

Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 13 | 15.8 | 82.1 | (43.7-140.4) | Male | 11 | 9.9 | 111.1 | (55.4-198.8) |
| Female | 4 | 6.0 | nc | (nc-nc) | Female | 11 | 8.3 | 132.8 | (66.2-237.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 3.2 | 187.3 | (68.4-407.6) | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 5 | 2.6 | 191.8 | (61.8-447.6) | Female | 2 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 9 | 8.7 | 103.5 | (47.2-196.5) |
| Female | 69 | 60.6 | 114.0 | (88.7-144.2) | Female | 7 | 7.9 | 88.8 | (35.6-182.9) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 3 | 2.7 | nc | (nc-nc) | Male | 6 | 6.3 | 94.7 | (34.6-206.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 18 | 23.7 | 75.8 | (44.9-119.9) | Female | 8 | 6.5 | 123.2 | (53.0-242.7) |
| Female | 38 | 23.0 | 165.6 | (117.1-227.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 4.7 | nc | (nc-nc) |
| Male | 6 | 4.2 | 144.2 | (52.7-313.9) | Female | 1 | 5.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 51 | 62.6 | 81.5 | (60.7-107.2) |
| Male | 3 | 1.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.1 | nc | (nc-nc) | Male | 9 | 3.9 | 229.7 | (104.8-436.1) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 2.4 | nc | (nc-nc) |
| Male | 7 | 7.4 | 94.1 | (37.7-194.0) | <u>Testis</u> | | | | |
| Female | 5 | 4.6 | 108.1 | (34.9-252.4) | Male | 3 | 2.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2.6 | nc | (nc-nc) | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 11 | 7.4 | 147.9 | (73.7-264.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 5.3 | 149.7 | (64.5-295.0) | Female | 12 | 12.9 | 93.0 | (48.0-162.5) |
| Female | 3 | 4.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 217 | 217.0 | 100.0 | (87.1-114.2) |
| Male | 3 | 3.6 | nc | (nc-nc) | Female | 237 | 207.8 | 114.1 | (100.0-129.5) |
| Female | 0 | 1.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 41 | 30.0 | 136.8 | (98.2-185.6) | | | | | |
| Female | 35 | 28.7 | 121.9 | (84.9-169.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 13 | 16.3 | 79.6 | (42.4-136.2) | Male | 17 | 11.6 | 146.0 | (85.0-233.7) |
| Female | 5 | 5.8 | 85.7 | (27.6-200.0) | Female | 16 | 9.9 | 161.0 | (91.9-261.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 4.0 | nc | (nc-nc) | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 2 | 3.1 | nc | (nc-nc) | Female | 2 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 8 | 10.0 | 80.2 | (34.5-158.0) |
| Female | 92 | 72.3 | 127.2 | (102.5-156.0) | Female | 13 | 8.1 | 159.6 | (84.9-272.9) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 3.5 | nc | (nc-nc) | Male | 4 | 7.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 24 | 25.7 | 93.3 | (59.8-138.9) | Female | 10 | 7.5 | 133.8 | (64.0-246.1) |
| Female | 17 | 22.4 | 76.0 | (44.3-121.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 9 | 5.1 | 177.2 | (80.9-336.4) |
| Male | 1 | 4.7 | nc | (nc-nc) | Female | 5 | 4.8 | 104.8 | (33.8-244.6) |
| Female | 0 | 1.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 61 | 69.9 | 87.3 | (66.8-112.2) |
| Male | 1 | 1.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.3 | nc | (nc-nc) | Male | 4 | 4.1 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 2.3 | nc | (nc-nc) |
| Male | 6 | 8.8 | 68.2 | (24.9-148.5) | <u>Testis</u> | | | | |
| Female | 5 | 5.0 | 99.7 | (32.1-232.6) | Male | 8 | 3.2 | 252.2 | (108.6-497.0) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 3.0 | nc | (nc-nc) | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 11 | 9.9 | 111.6 | (55.6-199.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 9 | 6.0 | 149.8 | (68.4-284.4) | Female | 15 | 15.2 | 98.6 | (55.2-162.7) |
| Female | 5 | 4.5 | 110.9 | (35.7-258.9) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 212 | 241.5 | 87.8 | (76.4-100.4) |
| Male | 5 | 4.3 | 116.6 | (37.6-272.2) | Female | 236 | 229.0 | 103.1 | (90.3-117.1) |
| Female | 1 | 1.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 15 | 32.0 | 46.9 | (26.2-77.3) | | | | | |
| Female | 25 | 28.9 | 86.6 | (56.0-127.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 12 | 12.6 | 95.5 | (49.3-166.9) | Male | 5 | 7.5 | 66.7 | (21.5-155.8) |
| Female | 5 | 4.4 | 113.2 | (36.5-264.2) | Female | 2 | 5.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 2.4 | nc | (nc-nc) | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 1 | 1.8 | nc | (nc-nc) | Female | 0 | 1.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 6 | 6.6 | 90.5 | (33.0-197.0) |
| Female | 41 | 44.2 | 92.8 | (66.6-125.9) | Female | 2 | 5.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 1.9 | nc | (nc-nc) | Male | 1 | 4.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 22 | 18.6 | 118.2 | (74.0-179.0) | Female | 4 | 4.7 | nc | (nc-nc) |
| Female | 17 | 16.5 | 102.7 | (59.8-164.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 5 | 3.7 | 134.5 | (43.4-314.0) |
| Male | 5 | 3.3 | 153.5 | (49.5-358.2) | Female | 2 | 3.6 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 50 | 49.1 | 101.7 | (75.5-134.1) |
| Male | 1 | 1.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Male | 6 | 3.1 | 195.5 | (71.4-425.5) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 1.7 | nc | (nc-nc) |
| Male | 9 | 5.7 | 157.1 | (71.7-298.3) | <u>Testis</u> | | | | |
| Female | 4 | 3.4 | nc | (nc-nc) | Male | 2 | 1.6 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 2.0 | nc | (nc-nc) | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 4 | 5.1 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 4.0 | nc | (nc-nc) | Female | 7 | 9.5 | 73.5 | (29.4-151.4) |
| Female | 2 | 3.0 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 177 | 168.8 | 104.8 | (90.0-121.5) |
| Male | 4 | 2.8 | nc | (nc-nc) | Female | 125 | 151.1 | 82.7 | (68.9-98.6) |
| Female | 2 | 0.9 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 26 | 23.9 | 108.7 | (71.0-159.2) | | | | | |
| Female | 22 | 21.5 | 102.1 | (64.0-154.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 17 | 12.5 | 136.1 | (79.3-218.0) | Male | 0 | 6.8 | nc | (nc-nc) |
| Female | 3 | 5.0 | nc | (nc-nc) | Female | 3 | 5.5 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 2.0 | nc | (nc-nc) | Male | 1 | 1.9 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) | Female | 0 | 1.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 2 | 6.1 | nc | (nc-nc) |
| Female | 42 | 42.5 | 98.9 | (71.3-133.7) | Female | 5 | 6.2 | 80.3 | (25.9-187.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 1.6 | nc | (nc-nc) | Male | 1 | 4.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 19 | 17.9 | 106.1 | (63.9-165.7) | Female | 7 | 4.7 | 149.2 | (59.8-307.5) |
| Female | 29 | 19.3 | 150.5 | (100.7-216.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 6 | 3.6 | 166.6 | (60.8-362.6) |
| Male | 5 | 3.1 | 163.9 | (52.8-382.5) | Female | 5 | 4.2 | 118.1 | (38.0-275.5) |
| Female | 1 | 1.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 59 | 45.1 | 130.8 | (99.6-168.7) |
| Male | 1 | 0.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.6 | nc | (nc-nc) | Male | 3 | 3.0 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 2.1 | nc | (nc-nc) |
| Male | 8 | 5.2 | 154.8 | (66.6-305.0) | <u>Testis</u> | | | | |
| Female | 5 | 3.5 | 141.2 | (45.5-329.6) | Male | 1 | 1.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 1.9 | nc | (nc-nc) | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 1 | 4.2 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 3.8 | 132.2 | (42.6-308.5) | Female | 10 | 9.1 | 110.0 | (52.7-202.4) |
| Female | 4 | 3.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 168 | 158.0 | 106.3 | (90.8-123.6) |
| Male | 3 | 2.5 | nc | (nc-nc) | Female | 172 | 156.1 | 110.2 | (94.4-128.0) |
| Female | 1 | 1.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 21 | 23.2 | 90.6 | (56.1-138.6) | | | | | |
| Female | 38 | 23.3 | 163.3 | (115.5-224.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 33 | 34.3 | 96.2 | (66.2-135.1) | Male | 15 | 20.1 | 74.6 | (41.7-123.0) |
| Female | 12 | 14.4 | 83.3 | (43.0-145.6) | Female | 17 | 17.4 | 97.9 | (57.0-156.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 6.2 | nc | (nc-nc) | Male | 4 | 5.4 | nc | (nc-nc) |
| Female | 7 | 5.4 | 128.6 | (51.5-264.9) | Female | 2 | 4.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 1.0 | nc | (nc-nc) | Male | 15 | 17.9 | 83.9 | (46.9-138.5) |
| Female | 140 | 130.7 | 107.1 | (90.1-126.4) | Female | 27 | 18.2 | 148.1 | (97.6-215.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 5.4 | nc | (nc-nc) | Male | 10 | 12.7 | 78.8 | (37.7-144.9) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 52 | 50.5 | 103.0 | (76.9-135.1) | Female | 19 | 14.3 | 133.3 | (80.2-208.2) |
| Female | 56 | 56.5 | 99.1 | (74.9-128.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 9 | 10.1 | 89.3 | (40.7-169.5) |
| Male | 1 | 8.7 | nc | (nc-nc) | Female | 15 | 12.2 | 122.5 | (68.5-202.1) |
| Female | 4 | 2.8 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 112 | 127.3 | 88.0 | (72.5-105.9) |
| Male | 2 | 2.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 3 | 2.0 | nc | (nc-nc) | Male | 8 | 8.5 | 94.7 | (40.8-186.6) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 4 | 6.1 | nc | (nc-nc) |
| Male | 17 | 15.1 | 112.5 | (65.5-180.2) | <u>Testis</u> | | | | |
| Female | 13 | 10.4 | 125.3 | (66.6-214.3) | Male | 2 | 4.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 9 | 5.4 | 167.7 | (76.5-318.4) | Male | 4 | 4.5 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) | Female | 13 | 14.2 | 91.6 | (48.7-156.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 13 | 10.9 | 118.9 | (63.2-203.3) | Female | 27 | 27.7 | 97.5 | (64.2-141.8) |
| Female | 11 | 9.7 | 113.3 | (56.5-202.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 408 | 449.3 | 90.8 | (82.2-100.1) |
| Male | 6 | 7.3 | 82.2 | (30.0-179.0) | Female | 484 | 467.0 | 103.6 | (94.6-113.3) |
| Female | 2 | 2.9 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 60 | 63.5 | 94.5 | (72.1-121.7) | | | | | |
| Female | 71 | 65.8 | 107.9 | (84.2-136.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 0.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 5 | 2.0 | 245.2 | (79.0-572.2) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Female | 4 | 2.9 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 1 | 0.3 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Female | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 9 | 9.5 | 94.8 | (43.3-180.0) |
| Female | 0 | 0.0 | nc | (nc-nc) | Female | 9 | 6.6 | 135.5 | (61.8-257.2) |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | | | | | |
| Female | 1 | 0.9 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 10 | 15.5 | 64.3 | (30.8-118.3) | Male | 11 | 9.9 | 110.7 | (55.2-198.2) |
| Female | 5 | 6.2 | 80.2 | (25.8-187.1) | Female | 9 | 8.7 | 103.0 | (47.0-195.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 3.3 | nc | (nc-nc) | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 2 | 2.7 | nc | (nc-nc) | Female | 3 | 1.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 9 | 8.7 | 103.7 | (47.3-196.9) |
| Female | 42 | 63.0 | 66.7 | (48.0-90.1) | Female | 13 | 8.2 | 159.4 | (84.8-272.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 2.9 | nc | (nc-nc) | Male | 11 | 6.2 | 176.6 | (88.1-316.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 19 | 23.4 | 81.4 | (49.0-127.0) | Female | 4 | 6.7 | nc | (nc-nc) |
| Female | 25 | 24.0 | 104.0 | (67.3-153.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 4.6 | nc | (nc-nc) |
| Male | 6 | 4.1 | 146.9 | (53.6-319.8) | Female | 8 | 5.2 | 153.7 | (66.2-302.8) |
| Female | 1 | 1.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 57 | 60.9 | 93.6 | (70.9-121.3) |
| Male | 1 | 1.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.2 | nc | (nc-nc) | Male | 3 | 3.9 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 2.6 | nc | (nc-nc) |
| Male | 9 | 7.4 | 121.5 | (55.5-230.7) | <u>Testis</u> | | | | |
| Female | 6 | 4.8 | 125.9 | (46.0-274.1) | Male | 5 | 2.6 | 191.4 | (61.7-446.7) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 2.6 | nc | (nc-nc) | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 4 | 7.9 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 5.3 | 94.0 | (30.3-219.4) | Female | 16 | 13.2 | 121.3 | (69.3-197.0) |
| Female | 5 | 4.5 | 111.9 | (36.0-261.0) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 201 | 213.8 | 94.0 | (81.5-108.0) |
| Male | 2 | 3.5 | nc | (nc-nc) | Female | 197 | 216.1 | 91.1 | (78.9-104.8) |
| Female | 2 | 1.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 28 | 29.5 | 95.0 | (63.1-137.3) | | | | | |
| Female | 31 | 29.3 | 105.8 | (71.9-150.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 17.3 | 34.7 | (12.7-75.4) | Male | 12 | 11.8 | 101.8 | (52.5-177.8) |
| Female | 6 | 7.2 | 83.1 | (30.3-180.9) | Female | 9 | 11.9 | 75.7 | (34.5-143.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 4.3 | nc | (nc-nc) | Male | 5 | 2.8 | 181.1 | (58.4-422.7) |
| Female | 1 | 3.8 | nc | (nc-nc) | Female | 3 | 2.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 14 | 10.5 | 133.1 | (72.7-223.4) |
| Female | 92 | 73.0 | 126.0 | (101.6-154.5) | Female | 12 | 10.1 | 118.9 | (61.4-207.7) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 4 | 3.6 | nc | (nc-nc) | Male | 5 | 7.1 | 70.4 | (22.7-164.2) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 22 | 26.1 | 84.3 | (52.8-127.7) | Female | 8 | 8.5 | 94.1 | (40.5-185.5) |
| Female | 20 | 27.9 | 71.7 | (43.8-110.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 5 | 5.2 | 96.8 | (31.2-225.9) |
| Male | 7 | 4.5 | 155.1 | (62.1-319.6) | Female | 0 | 6.0 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 77 | 67.2 | 114.5 | (90.4-143.2) |
| Male | 2 | 3.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 3.5 | nc | (nc-nc) | Male | 7 | 4.4 | 160.7 | (64.4-331.0) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 3.0 | nc | (nc-nc) |
| Male | 6 | 8.1 | 74.5 | (27.2-162.2) | <u>Testis</u> | | | | |
| Female | 4 | 5.6 | nc | (nc-nc) | Male | 4 | 6.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2.8 | nc | (nc-nc) | Male | 2 | 3.3 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) | Female | 7 | 12.2 | 57.2 | (22.9-117.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 7.1 | 99.3 | (39.8-204.5) | Female | 19 | 15.6 | 122.1 | (73.5-190.7) |
| Female | 2 | 5.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 210 | 248.0 | 84.7 | (73.6-96.9) |
| Male | 0 | 4.0 | nc | (nc-nc) | Female | 223 | 261.9 | 85.2 | (74.3-97.1) |
| Female | 1 | 1.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 12 | 32.4 | 37.0 | (19.1-64.7) | | | | | |
| Female | 13 | 33.7 | 38.6 | (20.5-66.0) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 28 | 32.6 | 85.8 | (57.0-124.0) | Male | 19 | 20.7 | 91.7 | (55.2-143.2) |
| Female | 10 | 12.7 | 79.0 | (37.8-145.3) | Female | 27 | 17.7 | 152.9 | (100.8-222.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 8 | 6.8 | 117.5 | (50.6-231.6) | Male | 5 | 5.3 | 94.5 | (30.5-220.6) |
| Female | 5 | 5.6 | 89.6 | (28.9-209.2) | Female | 5 | 3.9 | 128.9 | (41.5-300.9) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 1.0 | nc | (nc-nc) | Male | 16 | 18.1 | 88.2 | (50.4-143.3) |
| Female | 128 | 133.2 | 96.1 | (80.2-114.2) | Female | 18 | 16.7 | 108.0 | (64.0-170.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 5.8 | nc | (nc-nc) | Male | 12 | 13.8 | 87.1 | (44.9-152.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 43 | 49.6 | 86.7 | (62.8-116.9) | Female | 10 | 14.1 | 70.8 | (33.9-130.2) |
| Female | 40 | 49.0 | 81.6 | (58.3-111.1) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 14 | 9.9 | 141.7 | (77.4-237.7) |
| Male | 6 | 8.8 | 68.0 | (24.8-147.9) | Female | 11 | 10.6 | 103.9 | (51.8-186.0) |
| Female | 2 | 2.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 184 | 132.7 | 138.7 | (119.4-160.3) |
| Male | 2 | 2.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 2.1 | nc | (nc-nc) | Male | 7 | 8.1 | 86.7 | (34.7-178.6) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 3 | 5.2 | nc | (nc-nc) |
| Male | 12 | 15.9 | 75.5 | (39.0-132.0) | <u>Testis</u> | | | | |
| Female | 11 | 9.9 | 111.2 | (55.4-199.0) | Male | 2 | 4.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 5.6 | nc | (nc-nc) | Male | 8 | 5.0 | 160.1 | (68.9-315.5) |
| Female | 1 | 1.5 | nc | (nc-nc) | Female | 23 | 15.8 | 145.4 | (92.1-218.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 11.0 | 99.6 | (49.6-178.2) | Female | 24 | 28.2 | 85.0 | (54.5-126.5) |
| Female | 7 | 9.0 | 77.8 | (31.2-160.2) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 463 | 454.6 | 101.8 | (92.8-111.6) |
| Male | 6 | 7.7 | 77.5 | (28.3-168.7) | Female | 397 | 446.8 | 88.9 | (80.3-98.0) |
| Female | 1 | 2.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 46 | 62.6 | 73.5 | (53.8-98.0) | | | | | |
| Female | 35 | 60.2 | 58.2 | (40.5-80.9) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.1 | nc | (nc-nc) | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.0 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 0.4 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 0.1 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 4 | 1.1 | nc | (nc-nc) |
| Male | 0 | 0.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 0.0 | nc | (nc-nc) |
| Male | 0 | 0.1 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 0 | 0.0 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | Female | 1 | 0.2 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 0.1 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 13 | 3.9 | 331.4 | (176.3-566.7) |
| Male | 1 | 0.1 | nc | (nc-nc) | Female | 2 | 3.9 | nc | (nc-nc) |
| Female | 0 | 0.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 59 | 49.3 | 119.7 | (91.1-154.4) | Male | 35 | 29.0 | 120.6 | (84.0-167.7) |
| Female | 20 | 21.3 | 93.9 | (57.3-145.1) | Female | 25 | 26.6 | 93.9 | (60.8-138.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 8.9 | 67.2 | (24.5-146.3) | Male | 10 | 7.7 | 130.7 | (62.6-240.4) |
| Female | 5 | 8.2 | 61.3 | (19.8-143.0) | Female | 11 | 6.5 | 169.7 | (84.6-303.6) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 1.4 | nc | (nc-nc) | Male | 27 | 25.6 | 105.3 | (69.4-153.3) |
| Female | 204 | 196.5 | 103.8 | (90.1-119.1) | Female | 28 | 27.1 | 103.3 | (68.6-149.3) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 3 | 8.4 | nc | (nc-nc) | Male | 12 | 17.7 | 67.8 | (35.0-118.5) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 61 | 72.1 | 84.6 | (64.7-108.7) | Female | 19 | 21.3 | 89.3 | (53.7-139.5) |
| Female | 80 | 81.8 | 97.8 | (77.5-121.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 12 | 14.4 | 83.5 | (43.1-145.9) |
| Male | 8 | 12.4 | 64.7 | (27.9-127.5) | Female | 17 | 17.9 | 95.2 | (55.4-152.5) |
| Female | 5 | 4.2 | 119.7 | (38.6-279.3) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 169 | 184.7 | 91.5 | (78.2-106.4) |
| Male | 3 | 3.8 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 6 | 3.1 | 191.9 | (70.1-417.8) | Male | 10 | 12.1 | 82.9 | (39.7-152.4) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 9 | 8.7 | 102.9 | (47.0-195.3) |
| Male | 18 | 21.7 | 83.0 | (49.2-131.2) | <u>Testis</u> | | | | |
| Female | 11 | 15.6 | 70.5 | (35.2-126.2) | Male | 7 | 6.8 | 102.8 | (41.2-211.8) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 13 | 7.7 | 169.9 | (90.4-290.5) | Male | 10 | 6.7 | 150.2 | (71.9-276.3) |
| Female | 5 | 2.4 | 208.8 | (67.3-487.2) | Female | 32 | 22.4 | 142.6 | (97.5-201.3) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 18 | 15.6 | 115.3 | (68.3-182.3) | Female | 42 | 41.7 | 100.7 | (72.6-136.2) |
| Female | 13 | 14.3 | 91.2 | (48.5-156.0) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 611 | 647.7 | 94.3 | (87.0-102.1) |
| Male | 9 | 10.4 | 86.9 | (39.7-165.1) | Female | 684 | 697.6 | 98.1 | (90.8-105.7) |
| Female | 3 | 4.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 69 | 92.4 | 74.7 | (58.1-94.5) | | | | | |
| Female | 72 | 99.8 | 72.1 | (56.4-90.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 4.8 | nc | (nc-nc) | Male | 1 | 3.3 | nc | (nc-nc) |
| Female | 2 | 1.6 | nc | (nc-nc) | Female | 3 | 2.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 1.1 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 2.9 | nc | (nc-nc) |
| Female | 16 | 19.1 | 83.6 | (47.7-135.7) | Female | 4 | 2.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 0.9 | nc | (nc-nc) | Male | 1 | 2.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 9 | 7.5 | 120.3 | (54.9-228.4) | Female | 1 | 2.0 | nc | (nc-nc) |
| Female | 6 | 6.0 | 100.7 | (36.8-219.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 4 | 1.3 | nc | (nc-nc) | Male | 18 | 20.1 | 89.4 | (53.0-141.3) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 6 | 2.5 | 237.4 | (86.7-516.7) | Female | 3 | 3.9 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 65 | 69.9 | 93.0 | (71.7-118.5) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 59 | 61.0 | 96.7 | (73.6-124.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 1.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 1 | 1.2 | nc | (nc-nc) | Male | 65 | 69.9 | 93.0 | (71.7-118.5) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.2 | nc | (nc-nc) | Female | 59 | 61.0 | 96.7 | (73.6-124.7) |
| Female | 2 | 0.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 9.3 | 74.9 | (30.0-154.4) | Male | 65 | 69.9 | 93.0 | (71.7-118.5) |
| Female | 5 | 7.8 | 64.0 | (20.6-149.3) | Female | 59 | 61.0 | 96.7 | (73.6-124.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 2.5 | nc | (nc-nc) | Male | 0 | 1.7 | nc | (nc-nc) |
| Female | 4 | 0.9 | nc | (nc-nc) | Female | 0 | 1.4 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 0.6 | nc | (nc-nc) | Male | 2 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 1 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 1.5 | nc | (nc-nc) |
| Female | 7 | 10.0 | 69.7 | (27.9-143.7) | Female | 2 | 1.2 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.5 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 9 | 3.8 | 235.4 | (107.4-446.9) | Female | 0 | 1.0 | nc | (nc-nc) |
| Female | 8 | 3.4 | 238.6 | (102.7-470.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 0.8 | nc | (nc-nc) |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 11 | 10.4 | 105.5 | (52.6-188.8) |
| Male | 0 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 0.3 | nc | (nc-nc) |
| Male | 1 | 1.3 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 1 | 1.3 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Female | 3 | 2.1 | nc | (nc-nc) |
| Female | 2 | 0.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 34 | 35.9 | 94.6 | (65.5-132.2) |
| Male | 1 | 0.6 | nc | (nc-nc) | Female | 37 | 32.8 | 113.0 | (79.5-155.7) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 3 | 4.8 | nc | (nc-nc) | | | | | |
| Female | 3 | 4.3 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 2.1 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 1 | 1.0 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 7 | 7.8 | 89.9 | (36.0-185.2) | Female | 0 | 0.9 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 4 | 3.2 | nc | (nc-nc) | Female | 1 | 0.8 | nc | (nc-nc) |
| Female | 1 | 2.5 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 0.6 | nc | (nc-nc) |
| Male | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 8 | 8.1 | 98.5 | (42.4-194.2) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 0.3 | nc | (nc-nc) |
| Male | 0 | 1.0 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 2 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 1.0 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Female | 3 | 1.7 | nc | (nc-nc) |
| Female | 2 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 25 | 28.4 | 88.1 | (57.0-130.1) |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 17 | 24.8 | 68.7 | (40.0-110.0) |
| Female | 0 | 0.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 4 | 3.9 | nc | (nc-nc) | | | | | |
| Female | 1 | 3.2 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|----------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 21 | 13.4 | 156.5 | (96.9-239.3) | Male | 14 | 9.1 | 154.4 | (84.3-259.0) |
| Female | 5 | 4.7 | 105.9 | (34.1-247.2) | Female | 8 | 7.8 | 102.7 | (44.2-202.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 3.0 | nc | (nc-nc) | Male | 3 | 2.2 | nc | (nc-nc) |
| Female | 6 | 2.4 | 250.1 | (91.3-544.4) | Female | 2 | 1.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 7 | 7.8 | 89.6 | (35.9-184.7) |
| Female | 68 | 55.9 | 121.7 | (94.5-154.3) | Female | 12 | 6.5 | 184.8 | (95.4-322.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 2.7 | nc | (nc-nc) | Male | 6 | 5.8 | 102.9 | (37.6-224.0) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 24 | 20.6 | 116.3 | (74.5-173.1) | Female | 7 | 5.8 | 120.4 | (48.3-248.2) |
| Female | 21 | 17.6 | 119.0 | (73.7-182.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 5 | 4.1 | 122.7 | (39.5-286.3) |
| Male | 1 | 3.7 | nc | (nc-nc) | Female | 9 | 3.8 | 235.4 | (107.4-446.9) |
| Female | 0 | 0.9 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 49 | 55.2 | 88.7 | (65.6-117.3) |
| Male | 0 | 1.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 5 | 1.0 | 492.3 | (158.7-1149.0) | Male | 3 | 3.4 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 1.8 | nc | (nc-nc) |
| Male | 3 | 6.8 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 4.0 | nc | (nc-nc) | Male | 2 | 2.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2.3 | nc | (nc-nc) | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 10 | 7.7 | 130.7 | (62.6-240.3) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 5 | 4.7 | 106.1 | (34.2-247.5) | Female | 13 | 11.8 | 109.8 | (58.4-187.8) |
| Female | 3 | 3.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 174 | 191.8 | 90.7 | (77.8-105.3) |
| Male | 3 | 3.3 | nc | (nc-nc) | Female | 208 | 180.1 | 115.5 | (100.3-132.3) |
| Female | 0 | 1.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 12 | 26.1 | 45.9 | (23.7-80.2) | | | | | |
| Female | 26 | 23.7 | 109.6 | (71.6-160.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 19 | 14.2 | 134.0 | (80.7-209.3) | Male | 7 | 8.1 | 86.8 | (34.8-178.9) |
| Female | 7 | 5.6 | 124.6 | (49.9-256.8) | Female | 5 | 6.6 | 75.8 | (24.4-176.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 2.5 | nc | (nc-nc) | Male | 1 | 2.2 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) | Female | 4 | 1.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 8 | 7.2 | 110.6 | (47.6-217.9) |
| Female | 42 | 49.4 | 85.1 | (61.3-115.0) | Female | 6 | 7.1 | 84.8 | (31.0-184.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 2.0 | nc | (nc-nc) | Male | 3 | 4.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 25 | 20.5 | 121.8 | (78.8-179.8) | Female | 7 | 5.4 | 129.3 | (51.8-266.3) |
| Female | 22 | 21.9 | 100.3 | (62.8-151.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 4.1 | nc | (nc-nc) |
| Male | 2 | 3.5 | nc | (nc-nc) | Female | 8 | 4.8 | 167.6 | (72.2-330.2) |
| Female | 2 | 1.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 53 | 50.6 | 104.7 | (78.4-136.9) |
| Male | 2 | 1.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.8 | nc | (nc-nc) | Male | 4 | 3.5 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 2.4 | nc | (nc-nc) |
| Male | 4 | 6.0 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 4.0 | nc | (nc-nc) | Male | 1 | 1.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 2.1 | nc | (nc-nc) | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 2 | 5.4 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 6 | 4.5 | 133.3 | (48.7-290.1) | Female | 9 | 10.4 | 86.8 | (39.6-164.8) |
| Female | 7 | 3.8 | 184.3 | (73.9-379.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 186 | 181.2 | 102.6 | (88.4-118.5) |
| Male | 4 | 2.9 | nc | (nc-nc) | Female | 169 | 179.2 | 94.3 | (80.6-109.7) |
| Female | 2 | 1.1 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 28 | 25.8 | 108.3 | (72.0-156.6) | | | | | |
| Female | 31 | 25.6 | 121.0 | (82.2-171.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 43 | 40.5 | 106.3 | (76.9-143.2) | Male | 23 | 25.6 | 89.8 | (56.9-134.8) |
| Female | 17 | 16.7 | 101.7 | (59.2-162.9) | Female | 27 | 22.7 | 118.8 | (78.3-172.9) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 10 | 8.4 | 118.8 | (56.9-218.5) | Male | 3 | 6.4 | nc | (nc-nc) |
| Female | 10 | 7.2 | 139.7 | (66.9-256.9) | Female | 5 | 5.1 | 98.7 | (31.8-230.3) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | Male | 21 | 22.5 | 93.5 | (57.9-143.0) |
| Female | 165 | 162.0 | 101.8 | (86.9-118.6) | Female | 20 | 21.8 | 91.7 | (56.0-141.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 7.5 | nc | (nc-nc) | Male | 18 | 15.9 | 113.3 | (67.1-179.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 63 | 60.5 | 104.2 | (80.1-133.3) | Female | 21 | 17.5 | 120.2 | (74.4-183.8) |
| Female | 60 | 64.5 | 93.0 | (71.0-119.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 10 | 12.0 | 83.1 | (39.8-152.9) |
| Male | 17 | 10.5 | 161.3 | (93.9-258.2) | Female | 13 | 14.0 | 92.9 | (49.4-158.9) |
| Female | 1 | 3.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 126 | 157.3 | 80.1 | (66.7-95.4) |
| Male | 6 | 3.9 | 152.9 | (55.8-332.8) | <u>Stomach</u> | | | | |
| Female | 1 | 3.1 | nc | (nc-nc) | Male | 15 | 10.0 | 149.7 | (83.7-246.9) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 5 | 6.9 | 72.3 | (23.3-168.8) |
| Male | 22 | 19.0 | 115.8 | (72.6-175.4) | <u>Testis</u> | | | | |
| Female | 10 | 12.6 | 79.6 | (38.1-146.4) | Male | 5 | 7.1 | 70.0 | (22.5-163.3) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 6.6 | nc | (nc-nc) | Male | 5 | 6.4 | 78.5 | (25.3-183.2) |
| Female | 2 | 1.9 | nc | (nc-nc) | Female | 21 | 20.3 | 103.3 | (63.9-157.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 13 | 13.8 | 94.0 | (50.0-160.7) | Female | 30 | 34.2 | 87.8 | (59.2-125.4) |
| Female | 10 | 11.9 | 84.3 | (40.4-155.0) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 537 | 553.7 | 97.0 | (88.9-105.5) |
| Male | 10 | 9.0 | 110.8 | (53.1-203.9) | Female | 544 | 567.5 | 95.9 | (88.0-104.3) |
| Female | 5 | 3.4 | 146.3 | (47.2-341.5) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 86 | 76.7 | 112.1 | (89.7-138.5) | | | | | |
| Female | 81 | 78.3 | 103.5 | (82.2-128.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 23 | 21.9 | 105.0 | (66.5-157.5) | Male | 5 | 12.4 | 40.4 | (13.0-94.3) |
| Female | 9 | 8.3 | 108.5 | (49.5-206.0) | Female | 4 | 10.0 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 3 | 3.8 | nc | (nc-nc) | Male | 6 | 3.4 | 177.8 | (64.9-387.1) |
| Female | 7 | 3.1 | 222.3 | (89.0-458.0) | Female | 1 | 2.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 7 | 11.1 | 63.3 | (25.4-130.4) |
| Female | 51 | 76.4 | 66.8 | (49.7-87.8) | Female | 8 | 10.5 | 76.2 | (32.8-150.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 3.1 | nc | (nc-nc) | Male | 8 | 7.8 | 103.1 | (44.4-203.3) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 34 | 31.9 | 106.7 | (73.9-149.1) | Female | 7 | 8.3 | 84.3 | (33.8-173.8) |
| Female | 30 | 31.8 | 94.3 | (63.6-134.6) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 5 | 6.4 | 78.2 | (25.2-182.6) |
| Male | 9 | 5.5 | 164.5 | (75.1-312.2) | Female | 7 | 6.9 | 100.7 | (40.4-207.5) |
| Female | 3 | 1.6 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 68 | 81.7 | 83.2 | (64.6-105.5) |
| Male | 2 | 1.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.1 | nc | (nc-nc) | Male | 2 | 5.3 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 4 | 3.4 | nc | (nc-nc) |
| Male | 3 | 9.4 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 9 | 6.1 | 147.9 | (67.5-280.8) | Male | 6 | 2.3 | 257.3 | (94.0-560.1) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 3.4 | nc | (nc-nc) | Male | 3 | 2.7 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 6 | 8.2 | 73.1 | (26.7-159.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 6.8 | nc | (nc-nc) | Female | 24 | 16.4 | 146.2 | (93.7-217.6) |
| Female | 4 | 5.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 249 | 284.0 | 87.7 | (77.1-99.3) |
| Male | 8 | 4.5 | 177.1 | (76.3-349.1) | Female | 249 | 270.5 | 92.1 | (81.0-104.2) |
| Female | 0 | 1.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 31 | 40.9 | 75.9 | (51.5-107.7) | | | | | |
| Female | 51 | 39.0 | 130.6 | (97.3-171.8) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 5.7 | 104.9 | (38.3-228.3) | Male | 5 | 3.3 | 153.4 | (49.4-358.0) |
| Female | 1 | 2.1 | nc | (nc-nc) | Female | 4 | 2.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 1.0 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 2 | 0.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 2 | 2.9 | nc | (nc-nc) |
| Female | 8 | 20.3 | 39.5 | (17.0-77.8) | Female | 2 | 2.7 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 0.8 | nc | (nc-nc) | Male | 2 | 2.0 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 9 | 8.3 | 108.1 | (49.3-205.3) | Female | 0 | 2.2 | nc | (nc-nc) |
| Female | 14 | 7.9 | 178.2 | (97.3-299.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 1.4 | nc | (nc-nc) | Male | 3 | 1.7 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 2 | 1.8 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 16 | 22.0 | 72.7 | (41.5-118.0) |
| Female | 1 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 3 | 2.5 | nc | (nc-nc) | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 1 | 1.6 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 2 | 0.9 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 2 | 1.8 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 1.4 | nc | (nc-nc) | Female | 2 | 2.2 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | Female | 6 | 4.4 | 135.4 | (49.5-294.8) |
| Female | 2 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 12 | 10.8 | 110.6 | (57.1-193.3) | Male | 74 | 75.2 | 98.4 | (77.3-123.6) |
| Female | 15 | 10.5 | 142.8 | (79.9-235.6) | Female | 72 | 70.6 | 102.0 | (79.8-128.5) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 5 | 6.3 | 79.0 | (25.5-184.3) | Male | 2 | 4.1 | nc | (nc-nc) |
| Female | 3 | 2.7 | nc | (nc-nc) | Female | 2 | 3.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.4 | nc | (nc-nc) | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 2 | 3.6 | nc | (nc-nc) |
| Female | 22 | 25.7 | 85.6 | (53.6-129.6) | Female | 4 | 3.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 1.2 | nc | (nc-nc) | Male | 2 | 2.5 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 10 | 9.5 | 105.7 | (50.6-194.4) | Female | 6 | 2.8 | 215.9 | (78.8-470.0) |
| Female | 11 | 10.5 | 105.2 | (52.5-188.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 1.9 | nc | (nc-nc) |
| Male | 1 | 1.7 | nc | (nc-nc) | Female | 0 | 2.3 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 19 | 24.6 | 77.1 | (46.4-120.5) |
| Male | 0 | 0.7 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 1 | 1.6 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 1.1 | nc | (nc-nc) |
| Male | 2 | 3.0 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 3 | 2.0 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 1.0 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 6 | 3.3 | 182.3 | (66.6-396.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 2.2 | nc | (nc-nc) | Female | 2 | 5.4 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 76 | 87.3 | 87.0 | (68.6-108.9) |
| Male | 1 | 1.4 | nc | (nc-nc) | Female | 87 | 91.0 | 95.6 | (76.6-118.0) |
| Female | 2 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 15 | 12.1 | 124.3 | (69.5-205.0) | | | | | |
| Female | 13 | 12.5 | 103.7 | (55.1-177.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 83 | 73.9 | 112.4 | (89.5-139.3) | Male | 52 | 39.6 | 131.3 | (98.0-172.1) |
| Female | 19 | 25.9 | 73.2 | (44.1-114.4) | Female | 55 | 30.3 | 181.7 | (136.8-236.4) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 13 | 11.8 | 110.2 | (58.6-188.5) | Male | 8 | 11.1 | 72.0 | (31.0-141.8) |
| Female | 13 | 9.5 | 136.2 | (72.4-232.9) | Female | 9 | 7.9 | 113.9 | (52.0-216.3) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 2.0 | nc | (nc-nc) | Male | 34 | 35.8 | 95.0 | (65.8-132.7) |
| Female | 244 | 232.8 | 104.8 | (92.1-118.8) | Female | 24 | 32.4 | 74.0 | (47.4-110.2) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 9 | 9.2 | 97.6 | (44.5-185.2) | Male | 29 | 24.0 | 120.7 | (80.8-173.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 101 | 105.4 | 95.8 | (78.1-116.5) | Female | 24 | 25.4 | 94.7 | (60.6-140.9) |
| Female | 103 | 98.0 | 105.1 | (85.8-127.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 29 | 21.2 | 137.0 | (91.7-196.8) |
| Male | 11 | 17.8 | 61.8 | (30.8-110.6) | Female | 41 | 21.6 | 189.4 | (135.9-257.0) |
| Female | 3 | 5.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 369 | 263.8 | 139.9 | (126.0-154.9) |
| Male | 6 | 4.6 | 130.4 | (47.6-283.9) | <u>Stomach</u> | | | | |
| Female | 3 | 3.5 | nc | (nc-nc) | Male | 16 | 17.8 | 89.6 | (51.2-145.6) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 12 | 10.3 | 116.0 | (59.9-202.7) |
| Male | 39 | 30.0 | 130.0 | (92.4-177.7) | <u>Testis</u> | | | | |
| Female | 23 | 18.9 | 121.9 | (77.2-182.9) | Male | 6 | 6.9 | 87.2 | (31.8-189.9) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 10.9 | nc | (nc-nc) | Male | 4 | 8.0 | nc | (nc-nc) |
| Female | 4 | 2.9 | nc | (nc-nc) | Female | 13 | 24.3 | 53.5 | (28.4-91.5) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 28 | 22.1 | 126.4 | (84.0-182.8) | Female | 44 | 50.2 | 87.7 | (63.7-117.7) |
| Female | 25 | 16.8 | 148.7 | (96.2-219.5) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 1036 | 926.1 | 111.9 | (105.2-118.9) |
| Male | 10 | 14.4 | 69.7 | (33.4-128.1) | Female | 883 | 831.5 | 106.2 | (99.3-113.4) |
| Female | 8 | 5.1 | 155.9 | (67.1-307.1) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 115 | 136.0 | 84.6 | (69.8-101.5) | | | | | |
| Female | 122 | 123.3 | 99.0 | (82.2-118.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 5.4 | nc | (nc-nc) | Male | 4 | 3.4 | nc | (nc-nc) |
| Female | 1 | 1.9 | nc | (nc-nc) | Female | 1 | 2.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 1.1 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) | Female | 1 | 0.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 4 | 3.0 | nc | (nc-nc) |
| Female | 17 | 19.4 | 87.8 | (51.1-140.6) | Female | 3 | 2.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.9 | nc | (nc-nc) | Male | 2 | 2.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 6 | 8.1 | 74.1 | (27.1-161.3) | Female | 2 | 2.1 | nc | (nc-nc) |
| Female | 2 | 7.5 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 2 | 1.4 | nc | (nc-nc) | Male | 1 | 1.6 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 1 | 1.6 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 12 | 20.3 | 59.2 | (30.5-103.4) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 1 | 2.5 | nc | (nc-nc) | Male | 0 | 1.4 | nc | (nc-nc) |
| Female | 2 | 1.5 | nc | (nc-nc) | Female | 1 | 0.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 2 | 1.8 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) | Female | 0 | 2.4 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.2 | nc | (nc-nc) | Female | 1 | 4.0 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 15 | 10.1 | 147.9 | (82.7-244.0) | Male | 56 | 72.7 | 77.0 | (58.2-100.0) |
| Female | 11 | 9.2 | 119.6 | (59.6-214.0) | Female | 52 | 66.8 | 77.8 | (58.1-102.1) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 2.4 | nc | (nc-nc) | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 1 | 0.9 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 7 | 7.0 | 99.3 | (39.8-204.6) | Female | 2 | 0.8 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.3 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 3.5 | nc | (nc-nc) | Female | 1 | 0.7 | nc | (nc-nc) |
| Female | 2 | 2.3 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Female | 2 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Female | 3 | 9.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | | | | |
| Male | 2 | 0.4 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Female | 1 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Female | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 3 | 1.5 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 9 | 4.5 | 199.6 | (91.1-379.0) | Female | 28 | 31.9 | 87.7 | (58.2-126.7) |
| Female | 6 | 3.2 | 187.4 | (68.4-407.8) | Female | 27 | 23.1 | 117.0 | (77.1-170.2) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 16 | 20.5 | 78.1 | (44.6-126.8) | Male | 16 | 11.1 | 144.1 | (82.3-234.0) |
| Female | 6 | 5.9 | 101.1 | (36.9-220.0) | Female | 8 | 7.3 | 109.5 | (47.1-215.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 3.3 | nc | (nc-nc) | Male | 4 | 3.1 | nc | (nc-nc) |
| Female | 1 | 2.3 | nc | (nc-nc) | Female | 0 | 1.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 11 | 10.0 | 110.0 | (54.8-196.8) |
| Female | 69 | 56.1 | 122.9 | (95.7-155.6) | Female | 3 | 7.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 2.3 | nc | (nc-nc) | Male | 4 | 6.8 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 26 | 29.4 | 88.5 | (57.8-129.6) | Female | 9 | 6.0 | 149.1 | (68.0-283.1) |
| Female | 16 | 22.9 | 70.0 | (40.0-113.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 4 | 5.9 | nc | (nc-nc) |
| Male | 3 | 5.0 | nc | (nc-nc) | Female | 7 | 5.0 | 140.7 | (56.4-289.9) |
| Female | 1 | 1.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 63 | 73.7 | 85.5 | (65.7-109.4) |
| Male | 0 | 1.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.8 | nc | (nc-nc) | Male | 4 | 5.0 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 2.4 | nc | (nc-nc) |
| Male | 9 | 8.5 | 106.4 | (48.5-201.9) | <u>Testis</u> | | | | |
| Female | 2 | 4.4 | nc | (nc-nc) | Male | 2 | 1.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 3.0 | nc | (nc-nc) | Male | 4 | 2.3 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 9 | 6.1 | 148.1 | (67.6-281.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 6 | 6.2 | 97.3 | (35.5-211.8) | Female | 9 | 12.1 | 74.5 | (34.0-141.5) |
| Female | 2 | 4.0 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 223 | 258.2 | 86.4 | (75.4-98.5) |
| Male | 3 | 4.0 | nc | (nc-nc) | Female | 184 | 196.0 | 93.9 | (80.8-108.4) |
| Female | 3 | 1.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 25 | 37.7 | 66.3 | (42.9-97.8) | | | | | |
| Female | 23 | 27.7 | 83.0 | (52.6-124.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 9 | 11.2 | 80.6 | (36.8-153.0) | Male | 9 | 7.6 | 118.8 | (54.2-225.5) |
| Female | 4 | 3.9 | nc | (nc-nc) | Female | 12 | 6.6 | 182.6 | (94.2-319.0) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 2.6 | nc | (nc-nc) | Male | 3 | 1.8 | nc | (nc-nc) |
| Female | 6 | 2.0 | 297.2 | (108.5-646.8) | Female | 0 | 1.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 3 | 6.6 | nc | (nc-nc) |
| Female | 46 | 46.1 | 99.7 | (73.0-133.0) | Female | 4 | 5.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 3 | 2.3 | nc | (nc-nc) | Male | 5 | 4.9 | 103.1 | (33.2-240.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 19 | 17.2 | 110.7 | (66.6-172.8) | Female | 7 | 4.8 | 145.3 | (58.2-299.3) |
| Female | 9 | 14.9 | 60.5 | (27.6-114.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 3.4 | nc | (nc-nc) |
| Male | 6 | 3.0 | 198.5 | (72.5-432.1) | Female | 6 | 3.2 | 187.5 | (68.5-408.2) |
| Female | 1 | 0.8 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 40 | 43.9 | 91.1 | (65.1-124.0) |
| Male | 3 | 1.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.9 | nc | (nc-nc) | Male | 2 | 2.8 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 1.5 | nc | (nc-nc) |
| Male | 3 | 5.6 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 7 | 3.3 | 213.9 | (85.7-440.7) | Male | 4 | 2.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 1.9 | nc | (nc-nc) | Male | 1 | 2.0 | nc | (nc-nc) |
| Female | 0 | 0.5 | nc | (nc-nc) | Female | 7 | 6.5 | 107.4 | (43.0-221.4) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 4.0 | nc | (nc-nc) | Female | 10 | 9.6 | 104.5 | (50.0-192.1) |
| Female | 2 | 3.0 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 142 | 157.5 | 90.2 | (76.0-106.3) |
| Male | 1 | 2.7 | nc | (nc-nc) | Female | 149 | 149.4 | 99.7 | (84.3-117.1) |
| Female | 0 | 0.8 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 17 | 21.2 | 80.1 | (46.6-128.2) | | | | | |
| Female | 17 | 19.2 | 88.4 | (51.4-141.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 12 | 13.4 | 89.4 | (46.1-156.2) | Male | 7 | 9.1 | 77.0 | (30.9-158.7) |
| Female | 6 | 4.8 | 125.0 | (45.7-272.1) | Female | 10 | 7.7 | 130.5 | (62.5-240.1) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 3.1 | nc | (nc-nc) | Male | 2 | 2.2 | nc | (nc-nc) |
| Female | 5 | 2.4 | 208.5 | (67.2-486.7) | Female | 0 | 1.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 7 | 7.8 | 89.3 | (35.8-184.1) |
| Female | 49 | 55.2 | 88.8 | (65.7-117.5) | Female | 9 | 6.5 | 137.6 | (62.8-261.2) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 3 | 2.7 | nc | (nc-nc) | Male | 7 | 5.9 | 118.5 | (47.5-244.2) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 21 | 20.7 | 101.7 | (62.9-155.5) | Female | 7 | 5.8 | 121.1 | (48.5-249.5) |
| Female | 12 | 17.8 | 67.4 | (34.8-117.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 4.1 | nc | (nc-nc) |
| Male | 3 | 3.7 | nc | (nc-nc) | Female | 4 | 3.9 | nc | (nc-nc) |
| Female | 2 | 0.9 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 55 | 57.0 | 96.5 | (72.7-125.6) |
| Male | 2 | 1.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.0 | nc | (nc-nc) | Male | 8 | 3.3 | 239.7 | (103.2-472.4) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 3 | 1.8 | nc | (nc-nc) |
| Male | 7 | 6.9 | 101.6 | (40.7-209.3) | <u>Testis</u> | | | | |
| Female | 7 | 4.0 | 174.7 | (70.0-360.1) | Male | 3 | 2.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 2.4 | 211.0 | (68.0-492.4) | Male | 3 | 2.4 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 4 | 7.4 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 4.7 | 147.4 | (59.0-303.7) | Female | 14 | 11.9 | 118.0 | (64.5-198.0) |
| Female | 5 | 3.5 | 141.4 | (45.6-330.0) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 210 | 194.2 | 108.1 | (94.0-123.8) |
| Male | 2 | 3.3 | nc | (nc-nc) | Female | 202 | 179.9 | 112.3 | (97.3-128.9) |
| Female | 0 | 1.0 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 44 | 26.4 | 166.8 | (121.2-223.9) | | | | | |
| Female | 42 | 24.2 | 173.8 | (125.2-234.9) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 22 | 30.3 | 72.6 | (45.5-110.0) | Male | 23 | 17.3 | 132.9 | (84.2-199.4) |
| Female | 4 | 11.7 | nc | (nc-nc) | Female | 24 | 14.7 | 163.4 | (104.6-243.1) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 5.3 | 94.2 | (30.4-219.8) | Male | 1 | 4.7 | nc | (nc-nc) |
| Female | 4 | 4.6 | nc | (nc-nc) | Female | 1 | 3.6 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 0.9 | nc | (nc-nc) | Male | 16 | 15.4 | 103.6 | (59.2-168.2) |
| Female | 115 | 110.6 | 104.0 | (85.8-124.8) | Female | 20 | 15.0 | 133.3 | (81.4-205.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 4.7 | nc | (nc-nc) | Male | 8 | 10.8 | 74.4 | (32.0-146.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 38 | 44.1 | 86.2 | (61.0-118.4) | Female | 15 | 11.9 | 125.6 | (70.3-207.2) |
| Female | 45 | 45.5 | 98.9 | (72.1-132.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 7 | 8.8 | 79.4 | (31.8-163.6) |
| Male | 4 | 7.5 | nc | (nc-nc) | Female | 18 | 9.9 | 182.2 | (107.9-287.9) |
| Female | 3 | 2.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 99 | 112.0 | 88.4 | (71.8-107.6) |
| Male | 1 | 2.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 3 | 1.7 | nc | (nc-nc) | Male | 4 | 7.4 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 3 | 4.9 | nc | (nc-nc) |
| Male | 9 | 13.0 | 69.1 | (31.5-131.3) | <u>Testis</u> | | | | |
| Female | 6 | 8.7 | 69.2 | (25.3-150.7) | Male | 6 | 3.4 | 176.2 | (64.3-383.6) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 4.7 | nc | (nc-nc) | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 0 | 1.3 | nc | (nc-nc) | Female | 16 | 12.4 | 129.4 | (73.9-210.2) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 9.5 | 84.3 | (36.3-166.2) | Female | 20 | 23.5 | 85.3 | (52.1-131.7) |
| Female | 12 | 7.9 | 151.3 | (78.1-264.3) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 316 | 392.3 | 80.6 | (71.9-89.9) |
| Male | 3 | 6.2 | nc | (nc-nc) | Female | 382 | 388.5 | 98.3 | (88.7-108.7) |
| Female | 1 | 2.4 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 29 | 56.1 | 51.7 | (34.6-74.2) | | | | | |
| Female | 36 | 54.7 | 65.8 | (46.0-91.0) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 5 | 4.0 | 125.0 | (40.3-291.8) | Male | 3 | 3.1 | nc | (nc-nc) |
| Female | 1 | 1.3 | nc | (nc-nc) | Female | 4 | 2.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 1.1 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 3 | 0.8 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 2.6 | nc | (nc-nc) |
| Female | 16 | 17.5 | 91.6 | (52.3-148.8) | Female | 3 | 1.9 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 1.0 | nc | (nc-nc) | Male | 1 | 2.0 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 6.4 | 109.5 | (43.9-225.7) | Female | 2 | 1.8 | nc | (nc-nc) |
| Female | 4 | 5.1 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 3 | 1.2 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 0 | 1.1 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.5 | nc | (nc-nc) | Male | 20 | 17.4 | 114.6 | (70.0-177.1) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 2 | 2.3 | nc | (nc-nc) | Male | 2 | 1.0 | nc | (nc-nc) |
| Female | 2 | 1.2 | nc | (nc-nc) | Female | 2 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 0 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 1 | 1.6 | nc | (nc-nc) | Male | 2 | 0.9 | nc | (nc-nc) |
| Female | 0 | 1.1 | nc | (nc-nc) | Female | 7 | 2.8 | 249.5 | (100.0-514.1) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.1 | nc | (nc-nc) | Female | 5 | 3.6 | 140.4 | (45.3-327.7) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 7 | 7.9 | 88.2 | (35.4-181.8) | Male | 62 | 61.2 | 101.2 | (77.6-129.8) |
| Female | 7 | 6.6 | 105.4 | (42.2-217.2) | Female | 65 | 55.1 | 117.9 | (91.0-150.3) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 2.7 | nc | (nc-nc) | Male | 1 | 1.8 | nc | (nc-nc) |
| Female | 0 | 0.9 | nc | (nc-nc) | Female | 0 | 1.4 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 4 | 1.5 | nc | (nc-nc) |
| Female | 16 | 10.3 | 155.0 | (88.5-251.7) | Female | 1 | 1.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 1.2 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 4.2 | nc | (nc-nc) | Female | 0 | 1.1 | nc | (nc-nc) |
| Female | 7 | 3.5 | 198.4 | (79.5-408.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 11 | 11.6 | 95.1 | (47.4-170.2) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 0.4 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 1.4 | nc | (nc-nc) | Female | 4 | 2.2 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 37 | 38.8 | 95.4 | (67.1-131.5) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 40 | 34.0 | 117.6 | (84.0-160.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 0.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 3 | 5.3 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| Female | 4 | 4.7 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 2.9 | 205.9 | (75.2-448.3) | Male | 2 | 1.7 | nc | (nc-nc) |
| Female | 2 | 1.0 | nc | (nc-nc) | Female | 0 | 1.3 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 0.4 | nc | (nc-nc) | Female | 1 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 1.5 | nc | (nc-nc) |
| Female | 12 | 10.1 | 119.1 | (61.4-208.0) | Female | 1 | 1.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 6 | 4.3 | 139.5 | (50.9-303.7) | Female | 2 | 1.1 | nc | (nc-nc) |
| Female | 2 | 3.9 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 0.8 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.2 | nc | (nc-nc) | Male | 11 | 11.4 | 96.5 | (48.1-172.7) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 0 | 1.3 | nc | (nc-nc) | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.5 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 2 | 0.9 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 0 | 1.1 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Female | 10 | 2.2 | 461.4 | (220.9-848.6) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 4 | 5.5 | nc | (nc-nc) | Male | 38 | 38.9 | 97.8 | (69.2-134.2) |
| Female | 3 | 4.8 | nc | (nc-nc) | Female | 41 | 34.4 | 119.2 | (85.5-161.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 50 | 44.8 | 111.5 | (82.8-147.0) | Male | 25 | 26.6 | 94.1 | (60.9-138.9) |
| Female | 21 | 18.8 | 111.7 | (69.1-170.8) | Female | 26 | 23.2 | 112.0 | (73.1-164.1) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 14 | 8.4 | 167.6 | (91.6-281.2) | Male | 4 | 7.0 | nc | (nc-nc) |
| Female | 10 | 7.3 | 136.8 | (65.5-251.6) | Female | 3 | 5.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 3 | 1.3 | nc | (nc-nc) | Male | 15 | 23.6 | 63.7 | (35.6-105.0) |
| Female | 152 | 171.0 | 88.9 | (75.3-104.2) | Female | 29 | 23.9 | 121.4 | (81.3-174.3) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 3 | 7.3 | nc | (nc-nc) | Male | 18 | 16.5 | 109.2 | (64.7-172.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 49 | 65.9 | 74.3 | (55.0-98.3) | Female | 29 | 18.7 | 155.3 | (104.0-223.1) |
| Female | 64 | 73.4 | 87.1 | (67.1-111.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 9 | 13.1 | 68.5 | (31.3-130.0) |
| Male | 13 | 11.3 | 114.8 | (61.1-196.3) | Female | 12 | 15.9 | 75.4 | (38.9-131.7) |
| Female | 4 | 3.7 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 154 | 167.6 | 91.9 | (77.9-107.6) |
| Male | 3 | 3.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 3.0 | nc | (nc-nc) | Male | 5 | 11.0 | 45.4 | (14.6-105.9) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 3 | 8.0 | nc | (nc-nc) |
| Male | 22 | 19.9 | 110.8 | (69.4-167.7) | <u>Testis</u> | | | | |
| Female | 25 | 13.6 | 184.0 | (119.0-271.6) | Male | 9 | 6.1 | 147.3 | (67.2-279.6) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 10 | 7.0 | 142.9 | (68.4-262.9) | Male | 6 | 6.1 | 98.6 | (36.0-214.6) |
| Female | 4 | 2.1 | nc | (nc-nc) | Female | 22 | 19.5 | 112.9 | (70.7-170.9) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 11 | 14.5 | 75.9 | (37.8-135.8) | Female | 42 | 35.9 | 117.0 | (84.3-158.2) |
| Female | 11 | 12.9 | 85.4 | (42.6-152.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 556 | 591.1 | 94.1 | (86.4-102.2) |
| Male | 6 | 9.6 | 62.6 | (22.8-136.2) | Female | 633 | 612.4 | 103.4 | (95.5-111.7) |
| Female | 2 | 3.8 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 89 | 83.6 | 106.4 | (85.5-131.0) | | | | | |
| Female | 106 | 86.0 | 123.2 | (100.9-149.0) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 31 | 31.5 | 98.3 | (66.8-139.5) | Male | 23 | 22.5 | 102.3 | (64.8-153.5) |
| Female | 14 | 11.4 | 122.3 | (66.8-205.2) | Female | 11 | 18.6 | 59.1 | (29.4-105.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 6 | 7.7 | 78.0 | (28.5-169.7) | Male | 7 | 5.3 | 131.7 | (52.8-271.5) |
| Female | 7 | 5.8 | 120.2 | (48.1-247.6) | Female | 3 | 3.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 1.0 | nc | (nc-nc) | Male | 18 | 19.2 | 93.6 | (55.4-147.9) |
| Female | 132 | 134.3 | 98.3 | (82.2-116.6) | Female | 12 | 15.8 | 76.2 | (39.3-133.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 5 | 6.5 | 77.2 | (24.9-180.1) | Male | 21 | 14.9 | 140.5 | (86.9-214.8) |
| <u>Colon / Rectum</u> | | | | | Female | 13 | 6.2 | 210.7 | (112.1-360.4) |
| Male | 42 | 49.5 | 84.9 | (61.2-114.8) | <u>Ovary</u> | | | | |
| Female | 34 | 42.9 | 79.2 | (54.8-110.7) | Female | 15 | 14.1 | 106.5 | (59.6-175.7) |
| <u>Esophagus</u> | | | | | <u>Pancreas</u> | | | | |
| Male | 11 | 9.1 | 121.2 | (60.4-216.8) | Male | 7 | 9.8 | 71.1 | (28.5-146.5) |
| Female | 2 | 2.2 | nc | (nc-nc) | Female | 7 | 9.3 | 75.4 | (30.2-155.3) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 5 | 3.7 | 136.4 | (43.9-318.3) | Male | 148 | 139.2 | 106.3 | (89.9-124.9) |
| Female | 3 | 2.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | 4 | 7.9 | nc | (nc-nc) |
| Male | 25 | 17.0 | 147.2 | (95.2-217.3) | Female | 0 | 4.4 | nc | (nc-nc) |
| Female | 9 | 9.6 | 93.6 | (42.7-177.7) | <u>Testis</u> | | | | |
| <u>Larynx</u> | | | | | Male | 5 | 6.8 | 73.2 | (23.6-170.8) |
| Male | 4 | 5.8 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| Female | 3 | 1.5 | nc | (nc-nc) | Male | 6 | 6.2 | 97.5 | (35.6-212.2) |
| <u>Leukemia</u> | | | | | Female | 18 | 18.1 | 99.3 | (58.8-156.9) |
| Male | 9 | 11.6 | 77.5 | (35.4-147.1) | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Female | 16 | 8.5 | 188.2 | (107.5-305.6) | Female | 28 | 29.2 | 95.8 | (63.7-138.5) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 4 | 8.1 | nc | (nc-nc) | Male | 506 | 472.0 | 107.2 | (98.1-117.0) |
| Female | 7 | 2.4 | 293.3 | (117.5-604.4) | Female | 453 | 435.1 | 104.1 | (94.7-114.2) |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 86 | 62.6 | 137.4 | (109.9-169.7) | | | | | |
| Female | 73 | 57.2 | 127.7 | (100.1-160.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 11 | 7.5 | 146.4 | (73.0-262.0) | Male | 4 | 5.0 | nc | (nc-nc) |
| Female | 4 | 2.8 | nc | (nc-nc) | Female | 2 | 4.3 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 1.7 | nc | (nc-nc) | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 3 | 1.3 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 4.4 | nc | (nc-nc) |
| Female | 25 | 30.5 | 81.9 | (53.0-120.9) | Female | 8 | 3.8 | 209.7 | (90.3-413.3) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 1.5 | nc | (nc-nc) | Male | 1 | 3.1 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 12 | 11.4 | 104.9 | (54.1-183.2) | Female | 3 | 3.2 | nc | (nc-nc) |
| Female | 13 | 10.6 | 122.1 | (64.9-208.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 2.0 | nc | (nc-nc) | Male | 26 | 29.7 | 87.6 | (57.2-128.3) |
| Female | 3 | 0.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 0 | 1.5 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 8 | 3.7 | 215.9 | (92.9-425.4) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 5 | 2.3 | 220.9 | (71.2-515.5) | Female | 5 | 4.1 | 121.2 | (39.1-282.9) |
| <u>Larynx</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 2 | 1.3 | nc | (nc-nc) | Female | 8 | 6.4 | 124.8 | (53.7-245.8) |
| Female | 0 | 0.4 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Leukemia</u> | | | | | <u>All Sites / Types</u> | | | | |
| Male | 4 | 2.7 | nc | (nc-nc) | Male | 102 | 105.5 | 96.6 | (78.8-117.3) |
| Female | 1 | 2.1 | nc | (nc-nc) | Female | 116 | 102.3 | 113.4 | (93.7-136.0) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | | | | | |
| Male | 0 | 1.8 | nc | (nc-nc) | | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 24 | 14.3 | 167.8 | (107.5-249.7) | | | | | |
| Female | 19 | 13.8 | 137.4 | (82.7-214.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 1 | 1.3 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.4 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 1 | 0.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.0 | nc | (nc-nc) | Male | 1 | 0.7 | nc | (nc-nc) |
| Female | 6 | 4.7 | 127.8 | (46.7-278.1) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 0.2 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 0 | 2.0 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| Female | 1 | 1.4 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 1 | 0.3 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 7 | 5.4 | 129.1 | (51.7-266.1) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 1 | 0.3 | nc | (nc-nc) |
| Female | 1 | 0.3 | nc | (nc-nc) | Female | 0 | 0.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 1 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.3 | nc | (nc-nc) | Female | 2 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 2 | 2.5 | nc | (nc-nc) | Male | 14 | 18.3 | 76.6 | (41.8-128.5) |
| Female | 4 | 1.9 | nc | (nc-nc) | Female | 21 | 14.7 | 142.4 | (88.1-217.7) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 3.2 | nc | (nc-nc) | Male | 1 | 2.4 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) | Female | 1 | 2.0 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 1 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 2 | 2.1 | nc | (nc-nc) |
| Female | 16 | 14.4 | 111.0 | (63.4-180.3) | Female | 0 | 1.5 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.7 | nc | (nc-nc) | Male | 2 | 1.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 4 | 5.2 | nc | (nc-nc) | Female | 2 | 1.5 | nc | (nc-nc) |
| Female | 5 | 3.9 | 129.2 | (41.6-301.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 2 | 1.0 | nc | (nc-nc) | Male | 3 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 3 | 0.8 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 11 | 14.7 | 74.8 | (37.3-133.9) |
| Female | 1 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 2 | 1.9 | nc | (nc-nc) | Male | 0 | 0.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 3 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 0 | 1.2 | nc | (nc-nc) | Male | 2 | 0.7 | nc | (nc-nc) |
| Female | 1 | 0.8 | nc | (nc-nc) | Female | 4 | 2.1 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | Female | 1 | 3.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 5 | 6.4 | 78.6 | (25.3-183.3) | Male | 48 | 49.6 | 96.7 | (71.3-128.2) |
| Female | 4 | 5.2 | nc | (nc-nc) | Female | 43 | 43.6 | 98.7 | (71.4-132.9) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 352 | 450.9 | 78.1 | (70.1-86.7) | Male | 254 | 293.4 | 86.6 | (76.2-97.9) |
| Female | 157 | 187.8 | 83.6 | (71.0-97.7) | Female | 234 | 279.3 | 83.8 | (73.4-95.2) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 66 | 98.0 | 67.3 | (52.1-85.7) | Male | 80 | 71.7 | 111.5 | (88.4-138.8) |
| Female | 68 | 86.4 | 78.7 | (61.1-99.7) | Female | 79 | 56.8 | 139.2 | (110.2-173.5) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 18 | 12.9 | 139.8 | (82.8-220.9) | Male | 272 | 256.9 | 105.9 | (93.7-119.3) |
| Female | 1801 | 1852.9 | 97.2 | (92.8-101.8) | Female | 226 | 250.9 | 90.1 | (78.7-102.6) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 129 | 92.1 | 140.0 | (116.9-166.4) | Male | 224 | 174.8 | 128.1 | (111.9-146.0) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 716 | 673.3 | 106.3 | (98.7-114.4) | Female | 196 | 202.1 | 97.0 | (83.9-111.6) |
| Female | 778 | 717.8 | 108.4 | (100.9-116.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 149 | 133.3 | 111.8 | (94.6-131.3) |
| Male | 111 | 116.1 | 95.6 | (78.7-115.1) | Female | 156 | 155.9 | 100.0 | (85.0-117.0) |
| Female | 39 | 36.6 | 106.5 | (75.7-145.6) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 1944 | 1722.1 | 112.9 | (107.9-118.0) |
| Male | 49 | 54.9 | 89.2 | (66.0-118.0) | <u>Stomach</u> | | | | |
| Female | 52 | 47.4 | 109.8 | (82.0-144.0) | Male | 141 | 112.5 | 125.4 | (105.5-147.9) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 123 | 76.5 | 160.8 | (133.6-191.8) |
| Male | 222 | 210.1 | 105.7 | (92.2-120.5) | <u>Testis</u> | | | | |
| Female | 160 | 143.6 | 111.4 | (94.8-130.1) | Male | 75 | 105.7 | 70.9 | (55.8-88.9) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 76 | 72.3 | 105.1 | (82.8-131.5) | Male | 91 | 76.5 | 118.9 | (95.7-146.0) |
| Female | 24 | 22.1 | 108.8 | (69.7-161.9) | Female | 322 | 263.9 | 122.0 | (109.0-136.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 158 | 160.5 | 98.4 | (83.7-115.0) | Female | 380 | 391.9 | 97.0 | (87.5-107.2) |
| Female | 138 | 137.3 | 100.5 | (84.4-118.7) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 6706 | 6205.8 | 108.1 | (105.5-110.7) |
| Male | 192 | 99.8 | 192.4 | (166.1-221.6) | Female | 6684 | 6531.1 | 102.3 | (99.9-104.8) |
| Female | 53 | 38.6 | 137.3 | (102.9-179.6) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 978 | 848.0 | 115.3 | (108.2-122.8) | | | | | |
| Female | 910 | 890.1 | 102.2 | (95.7-109.1) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 24 | 25.4 | 94.3 | (60.4-140.4) | Male | 21 | 14.1 | 148.6 | (91.9-227.1) |
| Female | 14 | 9.2 | 152.4 | (83.2-255.7) | Female | 10 | 11.0 | 90.5 | (43.3-166.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 2 | 4.3 | nc | (nc-nc) | Male | 8 | 3.9 | 206.9 | (89.1-407.8) |
| Female | 6 | 3.5 | 171.4 | (62.6-373.0) | Female | 3 | 2.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 12 | 12.7 | 94.6 | (48.8-165.3) |
| Female | 84 | 83.1 | 101.1 | (80.6-125.1) | Female | 12 | 11.6 | 103.9 | (53.6-181.4) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 3.4 | nc | (nc-nc) | Male | 10 | 8.6 | 115.9 | (55.5-213.1) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 40 | 36.6 | 109.2 | (78.0-148.7) | Female | 8 | 9.1 | 88.1 | (37.9-173.6) |
| Female | 39 | 34.8 | 112.1 | (79.7-153.2) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 4 | 7.3 | nc | (nc-nc) |
| Male | 8 | 6.3 | 127.9 | (55.1-252.1) | Female | 6 | 7.7 | 78.4 | (28.6-170.6) |
| Female | 2 | 1.8 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 108 | 93.8 | 115.2 | (94.5-139.1) |
| Male | 3 | 1.9 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 1.4 | nc | (nc-nc) | Male | 4 | 6.2 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 4 | 3.7 | nc | (nc-nc) |
| Male | 5 | 10.7 | 46.8 | (15.1-109.3) | <u>Testis</u> | | | | |
| Female | 5 | 6.7 | 74.4 | (24.0-173.7) | Male | 2 | 3.1 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 6 | 3.8 | 156.0 | (57.0-339.6) | Male | 3 | 3.0 | nc | (nc-nc) |
| Female | 1 | 1.0 | nc | (nc-nc) | Female | 5 | 9.1 | 55.1 | (17.8-128.6) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 12 | 7.9 | 151.7 | (78.3-265.0) | Female | 24 | 18.0 | 133.0 | (85.2-197.9) |
| Female | 7 | 6.1 | 115.2 | (46.1-237.3) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 366 | 327.1 | 111.9 | (100.7-124.0) |
| Male | 6 | 5.1 | 117.3 | (42.8-255.3) | Female | 340 | 297.2 | 114.4 | (102.6-127.2) |
| Female | 5 | 1.8 | 272.1 | (87.7-635.1) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 59 | 47.5 | 124.3 | (94.6-160.3) | | | | | |
| Female | 65 | 43.5 | 149.3 | (115.2-190.3) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 3.0 | nc | (nc-nc) | Male | 4 | 2.5 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 4 | 2.1 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.9 | nc | (nc-nc) | Male | 0 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.6 | nc | (nc-nc) | Female | 0 | 0.3 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 2.1 | nc | (nc-nc) |
| Female | 12 | 14.4 | 83.2 | (42.9-145.4) | Female | 3 | 1.4 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 2 | 0.8 | nc | (nc-nc) | Male | 0 | 1.7 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 5.0 | nc | (nc-nc) | Female | 1 | 1.4 | nc | (nc-nc) |
| Female | 7 | 3.5 | 199.7 | (80.0-411.4) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 12 | 13.4 | 89.3 | (46.1-156.1) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 2 | 0.8 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.8 | nc | (nc-nc) | Female | 4 | 3.0 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Larynx</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 0.8 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 2 | 6.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 5 | 4.9 | 102.7 | (33.1-239.6) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 4 | 7.8 | nc | (nc-nc) | Male | 11 | 5.2 | 212.8 | (106.1-380.8) |
| Female | 3 | 2.4 | nc | (nc-nc) | Female | 6 | 3.9 | 152.4 | (55.6-331.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 1.7 | nc | (nc-nc) | Male | 1 | 1.3 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) | Female | 2 | 0.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.2 | nc | (nc-nc) | Male | 7 | 4.5 | 156.0 | (62.5-321.5) |
| Female | 45 | 29.9 | 150.4 | (109.7-201.3) | Female | 3 | 3.3 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 1.4 | nc | (nc-nc) | Male | 5 | 3.6 | 140.8 | (45.4-328.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 17 | 12.1 | 140.9 | (82.0-225.6) | Female | 2 | 3.1 | nc | (nc-nc) |
| Female | 9 | 8.9 | 100.6 | (45.9-190.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | | | | |
| Male | 2 | 2.2 | nc | (nc-nc) | Male | 0 | 2.4 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | Female | 1 | 1.9 | nc | (nc-nc) |
| <u>Hodgkin Lymphoma</u> | | | | | <u>Prostate</u> | | | | |
| Male | 0 | 0.7 | nc | (nc-nc) | Male | 34 | 33.4 | 101.9 | (70.5-142.3) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| <u>Kidney and Renal Pelvis</u> | | | | | Male | | | | |
| Male | 3 | 4.0 | nc | (nc-nc) | Male | 2 | 1.9 | nc | (nc-nc) |
| Female | 1 | 2.1 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Testis</u> | | | | |
| Male | 0 | 1.4 | nc | (nc-nc) | Male | 0 | 1.1 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Thyroid</u> | | | | |
| <u>Leukemia</u> | | | | | Male | | | | |
| Male | 2 | 2.7 | nc | (nc-nc) | Male | 0 | 1.3 | nc | (nc-nc) |
| Female | 2 | 1.8 | nc | (nc-nc) | Female | 4 | 3.8 | nc | (nc-nc) |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 3 | 2.0 | nc | (nc-nc) | Female | 6 | 6.3 | 94.7 | (34.6-206.2) |
| Female | 0 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Lung and Bronchus</u> | | | | | Male | | | | |
| Male | 6 | 15.3 | 39.3 | (14.3-85.5) | Male | 103 | 112.5 | 91.6 | (74.7-111.1) |
| Female | 14 | 12.0 | 116.7 | (63.7-195.8) | Female | 112 | 93.4 | 120.0 | (98.8-144.3) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 5 | 4.4 | 113.8 | (36.7-265.7) | Male | 4 | 2.8 | nc | (nc-nc) |
| Female | 3 | 1.5 | nc | (nc-nc) | Female | 1 | 2.2 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.9 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.7 | nc | (nc-nc) | Female | 0 | 0.5 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 3 | 2.5 | nc | (nc-nc) |
| Female | 22 | 16.6 | 132.4 | (82.9-200.4) | Female | 2 | 2.0 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 0.8 | nc | (nc-nc) | Male | 0 | 1.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 7 | 6.7 | 104.5 | (41.9-215.4) | Female | 2 | 1.7 | nc | (nc-nc) |
| Female | 4 | 5.5 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 1 | 1.3 | nc | (nc-nc) |
| Male | 0 | 1.2 | nc | (nc-nc) | Female | 0 | 1.2 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 22 | 18.4 | 119.3 | (74.7-180.6) |
| Male | 1 | 0.4 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.3 | nc | (nc-nc) | Male | 1 | 1.1 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 0.6 | nc | (nc-nc) |
| Male | 3 | 2.2 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 1.2 | nc | (nc-nc) | Male | 3 | 0.7 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Male | 0 | 0.7 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 3 | 2.1 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 4 | 1.5 | nc | (nc-nc) | Female | 3 | 3.6 | nc | (nc-nc) |
| Female | 0 | 1.0 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 63 | 62.2 | 101.3 | (77.9-129.6) |
| Male | 0 | 1.1 | nc | (nc-nc) | Female | 49 | 54.2 | 90.4 | (66.9-119.6) |
| Female | 1 | 0.3 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 7 | 8.5 | 81.9 | (32.8-168.9) | | | | | |
| Female | 4 | 7.4 | nc | (nc-nc) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 49 | 44.4 | 110.4 | (81.7-146.0) | Male | 29 | 24.9 | 116.6 | (78.1-167.5) |
| Female | 11 | 17.7 | 62.0 | (30.9-110.9) | Female | 24 | 21.0 | 114.5 | (73.3-170.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 8 | 7.6 | 104.6 | (45.0-206.1) | Male | 1 | 6.8 | nc | (nc-nc) |
| Female | 7 | 6.6 | 105.4 | (42.2-217.1) | Female | 3 | 5.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 1.2 | nc | (nc-nc) | Male | 21 | 22.3 | 94.4 | (58.4-144.2) |
| Female | 158 | 160.3 | 98.6 | (83.8-115.2) | Female | 19 | 22.2 | 85.5 | (51.5-133.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 9 | 6.4 | 140.1 | (63.9-265.9) | Male | 16 | 15.5 | 103.2 | (59.0-167.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 78 | 64.3 | 121.4 | (95.9-151.5) | Female | 17 | 17.4 | 97.5 | (56.7-156.0) |
| Female | 84 | 67.7 | 124.2 | (99.0-153.7) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 15 | 12.9 | 116.1 | (64.9-191.5) |
| Male | 11 | 11.1 | 99.5 | (49.6-178.0) | Female | 9 | 14.9 | 60.6 | (27.6-115.0) |
| Female | 4 | 3.5 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 149 | 166.3 | 89.6 | (75.8-105.2) |
| Male | 2 | 3.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 3 | 2.4 | nc | (nc-nc) | Male | 12 | 10.8 | 111.4 | (57.5-194.6) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 7 | 7.2 | 97.2 | (38.9-200.3) |
| Male | 18 | 19.0 | 94.6 | (56.0-149.5) | <u>Testis</u> | | | | |
| Female | 11 | 12.9 | 85.4 | (42.6-152.9) | Male | 2 | 4.8 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 6.8 | nc | (nc-nc) | Male | 5 | 5.4 | 93.4 | (30.1-217.9) |
| Female | 1 | 2.0 | nc | (nc-nc) | Female | 14 | 17.0 | 82.6 | (45.1-138.5) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 18 | 13.8 | 130.7 | (77.4-206.5) | Female | 28 | 34.6 | 80.9 | (53.8-117.0) |
| Female | 15 | 11.7 | 128.2 | (71.7-211.5) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 564 | 575.0 | 98.1 | (90.2-106.5) |
| Male | 3 | 9.1 | nc | (nc-nc) | Female | 563 | 571.6 | 98.5 | (90.5-107.0) |
| Female | 2 | 3.5 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 77 | 83.2 | 92.6 | (73.1-115.7) | | | | | |
| Female | 82 | 83.3 | 98.4 | (78.3-122.2) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 16 | 20.1 | 79.4 | (45.4-129.0) | Male | 15 | 10.0 | 149.7 | (83.7-247.0) |
| Female | 12 | 7.1 | 169.8 | (87.7-296.7) | Female | 12 | 7.4 | 162.9 | (84.1-284.5) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 5 | 2.8 | 176.8 | (57.0-412.6) | Male | 1 | 3.0 | nc | (nc-nc) |
| Female | 6 | 2.3 | 258.3 | (94.3-562.3) | Female | 3 | 2.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 0.5 | nc | (nc-nc) | Male | 9 | 9.2 | 97.5 | (44.5-185.1) |
| Female | 73 | 58.2 | 125.4 | (98.3-157.7) | Female | 11 | 8.5 | 129.4 | (64.5-231.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 2.1 | nc | (nc-nc) | Male | 9 | 5.9 | 153.0 | (69.8-290.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 28 | 28.1 | 99.5 | (66.1-143.9) | Female | 5 | 6.4 | 78.0 | (25.1-182.0) |
| Female | 23 | 27.3 | 84.3 | (53.4-126.5) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 7 | 5.6 | 124.0 | (49.7-255.5) |
| Male | 5 | 4.6 | 108.4 | (34.9-252.9) | Female | 6 | 6.0 | 99.9 | (36.5-217.5) |
| Female | 0 | 1.4 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 97 | 66.9 | 145.0 | (117.6-176.8) |
| Male | 1 | 1.0 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 0.7 | nc | (nc-nc) | Male | 3 | 4.8 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 2 | 3.0 | nc | (nc-nc) |
| Male | 5 | 7.5 | 66.3 | (21.4-154.8) | <u>Testis</u> | | | | |
| Female | 2 | 4.8 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 3 | 2.8 | nc | (nc-nc) | Male | 0 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.7 | nc | (nc-nc) | Female | 4 | 5.4 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 5.7 | 122.2 | (49.0-251.9) | Female | 13 | 12.4 | 105.1 | (55.9-179.8) |
| Female | 6 | 4.5 | 134.2 | (49.0-292.0) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 278 | 240.0 | 115.8 | (102.6-130.3) |
| Male | 2 | 3.6 | nc | (nc-nc) | Female | 235 | 214.9 | 109.4 | (95.8-124.3) |
| Female | 1 | 1.4 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 41 | 36.1 | 113.6 | (81.5-154.1) | | | | | |
| Female | 30 | 32.1 | 93.5 | (63.1-133.5) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 18 | 19.5 | 92.5 | (54.8-146.2) | Male | 17 | 14.1 | 120.7 | (70.3-193.3) |
| Female | 7 | 6.8 | 102.8 | (41.2-211.8) | Female | 19 | 10.6 | 178.8 | (107.6-279.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 4.8 | nc | (nc-nc) | Male | 0 | 3.2 | nc | (nc-nc) |
| Female | 3 | 3.4 | nc | (nc-nc) | Female | 0 | 2.1 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.6 | nc | (nc-nc) | Male | 14 | 12.1 | 116.0 | (63.4-194.7) |
| Female | 85 | 74.0 | 114.8 | (91.7-142.0) | Female | 11 | 9.3 | 118.5 | (59.1-212.0) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 6 | 3.6 | 168.1 | (61.4-365.9) | Male | 7 | 8.9 | 78.3 | (31.4-161.4) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 33 | 30.4 | 108.6 | (74.8-152.6) | Female | 14 | 7.9 | 176.3 | (96.3-295.8) |
| Female | 28 | 25.8 | 108.6 | (72.2-157.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 9 | 6.0 | 150.7 | (68.8-286.1) |
| Male | 6 | 5.4 | 110.4 | (40.3-240.3) | Female | 2 | 5.6 | nc | (nc-nc) |
| Female | 2 | 1.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 67 | 80.8 | 82.9 | (64.2-105.3) |
| Male | 1 | 2.6 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 1.8 | nc | (nc-nc) | Male | 4 | 4.9 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 2.7 | nc | (nc-nc) |
| Male | 11 | 10.2 | 107.5 | (53.6-192.4) | <u>Testis</u> | | | | |
| Female | 6 | 5.5 | 109.2 | (39.9-237.6) | Male | 6 | 5.1 | 117.8 | (43.0-256.4) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 3.4 | 145.2 | (46.8-338.8) | Male | 7 | 4.0 | 177.0 | (70.9-364.6) |
| Female | 1 | 0.9 | nc | (nc-nc) | Female | 15 | 10.3 | 145.6 | (81.4-240.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 8 | 7.3 | 109.7 | (47.3-216.3) | Female | 19 | 15.7 | 120.9 | (72.7-188.8) |
| Female | 4 | 5.1 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 286 | 286.7 | 99.7 | (88.5-112.0) |
| Male | 4 | 4.9 | nc | (nc-nc) | Female | 271 | 249.1 | 108.8 | (96.2-122.6) |
| Female | 0 | 1.4 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 32 | 37.9 | 84.5 | (57.8-119.3) | | | | | |
| Female | 35 | 33.3 | 105.2 | (73.3-146.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 6 | 3.7 | 164.2 | (60.0-357.5) | Male | 1 | 2.3 | nc | (nc-nc) |
| Female | 3 | 1.2 | nc | (nc-nc) | Female | 1 | 1.8 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 2 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.6 | nc | (nc-nc) | Female | 1 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 2.0 | nc | (nc-nc) |
| Female | 12 | 13.1 | 91.5 | (47.2-159.8) | Female | 1 | 1.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.6 | nc | (nc-nc) | Male | 2 | 1.6 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 5 | 5.6 | 90.0 | (29.0-210.0) | Female | 0 | 1.4 | nc | (nc-nc) |
| Female | 5 | 4.5 | 111.3 | (35.9-259.8) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 1.1 | nc | (nc-nc) |
| Male | 1 | 1.0 | nc | (nc-nc) | Female | 1 | 1.0 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 9 | 14.8 | 60.8 | (27.7-115.4) |
| Male | 1 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 1 | 0.2 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 0.5 | nc | (nc-nc) |
| Male | 1 | 1.8 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 1 | 0.9 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 0.6 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 1.7 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 1 | 1.2 | nc | (nc-nc) | Female | 1 | 2.8 | nc | (nc-nc) |
| Female | 1 | 0.9 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 48 | 51.0 | 94.1 | (69.4-124.8) |
| Male | 0 | 0.9 | nc | (nc-nc) | Female | 42 | 43.0 | 97.6 | (70.3-131.9) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 9 | 7.0 | 128.8 | (58.8-244.6) | | | | | |
| Female | 6 | 5.7 | 105.5 | (38.5-229.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 84 | 84.7 | 99.1 | (79.1-122.7) | Male | 35 | 53.4 | 65.6 | (45.7-91.2) |
| Female | 27 | 33.4 | 80.7 | (53.2-117.4) | Female | 41 | 48.1 | 85.3 | (61.2-115.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 17 | 18.1 | 93.9 | (54.7-150.4) | Male | 19 | 13.5 | 140.9 | (84.8-220.0) |
| Female | 16 | 15.5 | 103.1 | (58.9-167.4) | Female | 8 | 10.2 | 78.7 | (33.9-155.1) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 2 | 2.5 | nc | (nc-nc) | Male | 44 | 47.1 | 93.5 | (67.9-125.5) |
| Female | 295 | 339.8 | 86.8 | (77.2-97.3) | Female | 43 | 44.4 | 96.8 | (70.0-130.3) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 34 | 15.8 | 214.9 | (148.8-300.4) | Male | 35 | 33.4 | 104.7 | (72.9-145.6) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 136 | 126.5 | 107.5 | (90.2-127.1) | Female | 43 | 36.6 | 117.4 | (84.9-158.1) |
| Female | 152 | 127.9 | 118.8 | (100.7-139.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 26 | 25.2 | 103.1 | (67.3-151.0) |
| Male | 38 | 22.1 | 171.7 | (121.5-235.7) | Female | 32 | 27.8 | 115.3 | (78.9-162.8) |
| Female | 7 | 6.5 | 107.5 | (43.1-221.5) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 269 | 332.1 | 81.0 | (71.6-91.3) |
| Male | 5 | 8.6 | 58.3 | (18.8-136.0) | <u>Stomach</u> | | | | |
| Female | 3 | 7.1 | nc | (nc-nc) | Male | 29 | 21.0 | 138.4 | (92.6-198.7) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 16 | 13.5 | 118.2 | (67.5-192.0) |
| Male | 41 | 39.8 | 103.1 | (74.0-139.9) | <u>Testis</u> | | | | |
| Female | 26 | 26.0 | 100.1 | (65.4-146.7) | Male | 15 | 14.9 | 100.6 | (56.3-166.0) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 16 | 13.9 | 115.3 | (65.9-187.3) | Male | 14 | 13.2 | 106.1 | (58.0-178.0) |
| Female | 5 | 4.0 | 124.3 | (40.0-290.0) | Female | 56 | 44.3 | 126.5 | (95.5-164.3) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 30 | 29.7 | 101.0 | (68.1-144.2) | Female | 65 | 72.6 | 89.5 | (69.1-114.1) |
| Female | 17 | 24.6 | 69.2 | (40.3-110.9) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 1164 | 1164.4 | 100.0 | (94.3-105.9) |
| Male | 21 | 19.0 | 110.6 | (68.4-169.1) | Female | 1196 | 1171.7 | 102.1 | (96.4-108.0) |
| Female | 5 | 6.9 | 72.4 | (23.3-169.0) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 187 | 160.8 | 116.3 | (100.2-134.2) | | | | | |
| Female | 186 | 159.6 | 116.6 | (100.4-134.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|-------------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 2 | 3.5 | nc | (nc-nc) | Male | 0 | 2.1 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 2 | 1.7 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 1 | 0.7 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | Female | 0 | 0.4 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 1.9 | nc | (nc-nc) |
| Female | 15 | 12.7 | 118.3 | (66.2-195.2) | Female | 1 | 1.6 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 1 | 0.5 | nc | (nc-nc) | Male | 0 | 1.4 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 2 | 5.3 | nc | (nc-nc) | Female | 2 | 1.4 | nc | (nc-nc) |
| Female | 7 | 4.6 | 153.1 | (61.3-315.4) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 2 | 1.1 | nc | (nc-nc) |
| Male | 0 | 0.9 | nc | (nc-nc) | Female | 0 | 1.0 | nc | (nc-nc) |
| Female | 1 | 0.2 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 10 | 13.6 | 73.4 | (35.1-135.0) |
| Male | 0 | 0.3 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.2 | nc | (nc-nc) | Male | 0 | 0.9 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 0.5 | nc | (nc-nc) |
| Male | 5 | 1.6 | 307.1 | (99.0-716.7) | <u>Testis</u> | | | | |
| Female | 0 | 1.0 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 0.6 | nc | (nc-nc) | Male | 1 | 0.5 | nc | (nc-nc) |
| Female | 0 | 0.2 | nc | (nc-nc) | Female | 0 | 1.5 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 1.2 | nc | (nc-nc) | Female | 2 | 2.7 | nc | (nc-nc) |
| Female | 2 | 0.8 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 38 | 47.5 | 79.9 | (56.6-109.7) |
| Male | 1 | 0.8 | nc | (nc-nc) | Female | 53 | 42.8 | 123.9 | (92.8-162.1) |
| Female | 0 | 0.2 | nc | (nc-nc) | <u>Lung and Bronchus</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | <u>Bladder, Urinary</u> | | | | |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Male | 2 | 3.5 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | Female | 0 | 1.2 | nc | (nc-nc) |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | <u>Brain and Other Nervous System</u> | | | | |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Male | 1 | 0.7 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | Female | 1 | 0.5 | nc | (nc-nc) |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | <u>Breast</u> | | | | |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Male | 0 | 0.1 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | Female | 15 | 12.7 | 118.3 | (66.2-195.2) |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | <u>Cervix Uteri</u> | | | | |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 1 | 0.5 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Colon / Rectum</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 2 | 5.3 | nc | (nc-nc) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 7 | 4.6 | 153.1 | (61.3-315.4) |
| <u>Lung and Bronchus</u> | | | | | <u>Esophagus</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 0 | 0.9 | nc | (nc-nc) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 1 | 0.2 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Hodgkin Lymphoma</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Kidney and Renal Pelvis</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 5 | 1.6 | 307.1 | (99.0-716.7) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 0 | 1.0 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Larynx</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 1 | 0.6 | nc | (nc-nc) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Leukemia</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 0 | 1.2 | nc | (nc-nc) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 2 | 0.8 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Liver and Intrahepatic Bile Ducts</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 1 | 0.8 | nc | (nc-nc) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 0 | 0.2 | nc | (nc-nc) |
| <u>Lung and Bronchus</u> | | | | | <u>Lung and Bronchus</u> | | | | |
| Male | 7 | 6.7 | 104.2 | (41.8-214.8) | Male | 7 | 6.7 | 104.2 | (41.8-214.8) |
| Female | 16 | 6.1 | 263.8 | (150.7-428.4) | Female | 16 | 6.1 | 263.8 | (150.7-428.4) |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 44 | 52.9 | 83.1 | (60.4-111.6) | Male | 51 | 32.8 | 155.3 | (115.6-204.2) |
| Female | 22 | 22.3 | 98.6 | (61.8-149.3) | Female | 52 | 32.1 | 162.1 | (121.0-212.6) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 11 | 10.4 | 106.2 | (52.9-190.0) | Male | 5 | 8.4 | 59.7 | (19.2-139.3) |
| Female | 10 | 9.6 | 103.9 | (49.7-191.0) | Female | 4 | 6.8 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 1.5 | nc | (nc-nc) | Male | 42 | 28.9 | 145.5 | (104.9-196.7) |
| Female | 248 | 219.3 | 113.1 | (99.4-128.1) | Female | 38 | 29.5 | 128.9 | (91.2-176.9) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 7 | 10.4 | 67.2 | (26.9-138.5) | Male | 14 | 20.3 | 69.1 | (37.7-115.9) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 58 | 78.6 | 73.8 | (56.0-95.4) | Female | 30 | 23.9 | 125.6 | (84.7-179.3) |
| Female | 73 | 87.5 | 83.4 | (65.4-104.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 16 | 15.6 | 102.3 | (58.4-166.1) |
| Male | 7 | 13.6 | 51.5 | (20.6-106.2) | Female | 16 | 18.8 | 85.1 | (48.6-138.2) |
| Female | 4 | 4.3 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 214 | 201.9 | 106.0 | (92.3-121.2) |
| Male | 6 | 5.2 | 114.9 | (42.0-250.1) | <u>Stomach</u> | | | | |
| Female | 7 | 4.9 | 143.6 | (57.5-295.9) | Male | 9 | 13.1 | 68.7 | (31.3-130.4) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 9 | 9.5 | 95.2 | (43.4-180.7) |
| Male | 26 | 24.0 | 108.3 | (70.7-158.7) | <u>Testis</u> | | | | |
| Female | 18 | 16.8 | 107.3 | (63.6-169.6) | Male | 15 | 9.6 | 155.5 | (86.9-256.4) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 5 | 8.5 | 59.0 | (19.0-137.7) | Male | 18 | 8.0 | 225.4 | (133.5-356.2) |
| Female | 1 | 2.6 | nc | (nc-nc) | Female | 47 | 29.3 | 160.3 | (117.8-213.1) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 25 | 17.7 | 141.6 | (91.6-209.0) | Female | 56 | 46.4 | 120.6 | (91.1-156.6) |
| Female | 18 | 15.8 | 113.6 | (67.3-179.6) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 689 | 714.0 | 96.5 | (89.4-104.0) |
| Male | 10 | 11.6 | 86.6 | (41.4-159.2) | Female | 815 | 769.4 | 105.9 | (98.8-113.5) |
| Female | 4 | 4.7 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 66 | 98.7 | 66.9 | (51.7-85.1) | | | | | |
| Female | 80 | 103.0 | 77.7 | (61.6-96.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|------------------------------------------|------------|------------|------------|---------------|-------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 3 | 2.4 | nc | (nc-nc) | Male | 1 | 1.4 | nc | (nc-nc) |
| Female | 0 | 0.8 | nc | (nc-nc) | Female | 0 | 1.1 | nc | (nc-nc) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 0 | 0.4 | nc | (nc-nc) | Male | 0 | 0.4 | nc | (nc-nc) |
| Female | 0 | 0.3 | nc | (nc-nc) | Female | 1 | 0.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 0 | 0.1 | nc | (nc-nc) | Male | 1 | 1.2 | nc | (nc-nc) |
| Female | 7 | 8.2 | 85.0 | (34.0-175.0) | Female | 0 | 1.0 | nc | (nc-nc) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 0 | 0.4 | nc | (nc-nc) | Male | 1 | 0.9 | nc | (nc-nc) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 3 | 3.5 | nc | (nc-nc) | Female | 0 | 0.9 | nc | (nc-nc) |
| Female | 3 | 2.9 | nc | (nc-nc) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 0 | 0.7 | nc | (nc-nc) |
| Male | 1 | 0.6 | nc | (nc-nc) | Female | 0 | 0.6 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 5 | 9.2 | 54.2 | (17.5-126.6) |
| Male | 0 | 0.2 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 0 | 0.1 | nc | (nc-nc) | Male | 0 | 0.6 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 0 | 0.3 | nc | (nc-nc) |
| Male | 1 | 1.1 | nc | (nc-nc) | <u>Testis</u> | | | | |
| Female | 0 | 0.6 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 1 | 0.4 | nc | (nc-nc) | Male | 0 | 0.3 | nc | (nc-nc) |
| Female | 0 | 0.1 | nc | (nc-nc) | Female | 0 | 1.0 | nc | (nc-nc) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 0 | 0.8 | nc | (nc-nc) | Female | 3 | 1.8 | nc | (nc-nc) |
| Female | 1 | 0.5 | nc | (nc-nc) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 25 | 31.7 | 78.8 | (51.0-116.4) |
| Male | 0 | 0.5 | nc | (nc-nc) | Female | 24 | 27.4 | 87.6 | (56.1-130.3) |
| Female | 0 | 0.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 2 | 4.4 | nc | (nc-nc) | | | | | |
| Female | 5 | 3.7 | 134.9 | (43.5-314.7) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 23 | 25.2 | 91.1 | (57.8-136.8) | Male | 19 | 15.7 | 121.3 | (73.0-189.4) |
| Female | 6 | 9.1 | 66.3 | (24.2-144.3) | Female | 9 | 12.6 | 71.5 | (32.6-135.8) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 8 | 5.0 | 159.6 | (68.7-314.6) | Male | 3 | 4.1 | nc | (nc-nc) |
| Female | 3 | 4.0 | nc | (nc-nc) | Female | 2 | 2.7 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 15 | 13.6 | 110.3 | (61.7-181.9) |
| Female | 90 | 94.9 | 94.9 | (76.3-116.6) | Female | 11 | 11.8 | 93.6 | (46.7-167.5) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 5 | 4.1 | 121.4 | (39.1-283.3) | Male | 5 | 10.2 | 49.2 | (15.9-114.8) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 27 | 37.8 | 71.4 | (47.0-103.9) | Female | 3 | 10.1 | nc | (nc-nc) |
| Female | 39 | 33.0 | 118.0 | (83.9-161.3) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 3 | 7.6 | nc | (nc-nc) |
| Male | 8 | 6.8 | 117.7 | (50.7-231.8) | Female | 9 | 7.3 | 123.0 | (56.1-233.6) |
| Female | 3 | 1.8 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 113 | 108.0 | 104.7 | (86.2-125.8) |
| Male | 2 | 2.1 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 1.5 | nc | (nc-nc) | Male | 4 | 6.1 | nc | (nc-nc) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 1 | 3.3 | nc | (nc-nc) |
| Male | 7 | 12.2 | 57.4 | (23.0-118.3) | <u>Testis</u> | | | | |
| Female | 7 | 7.2 | 97.4 | (39.0-200.6) | Male | 6 | 3.6 | 165.1 | (60.3-359.4) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 4 | 4.4 | nc | (nc-nc) | Male | 4 | 3.8 | nc | (nc-nc) |
| Female | 0 | 1.2 | nc | (nc-nc) | Female | 13 | 11.3 | 115.1 | (61.2-196.8) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 13 | 8.3 | 157.0 | (83.5-268.5) | Female | 23 | 21.2 | 108.6 | (68.8-163.0) |
| Female | 8 | 6.1 | 130.8 | (56.3-257.8) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 347 | 354.9 | 97.8 | (87.8-108.6) |
| Male | 6 | 5.8 | 103.6 | (37.8-225.4) | Female | 323 | 317.9 | 101.6 | (90.8-113.3) |
| Female | 1 | 1.8 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 53 | 49.8 | 106.4 | (79.7-139.1) | | | | | |
| Female | 50 | 45.3 | 110.3 | (81.9-145.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 53 | 73.7 | 71.9 | (53.9-94.1) | Male | 47 | 49.7 | 94.5 | (69.4-125.7) |
| Female | 27 | 30.0 | 90.0 | (59.3-130.9) | Female | 41 | 48.2 | 85.0 | (61.0-115.3) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 13 | 16.6 | 78.2 | (41.6-133.8) | Male | 8 | 11.8 | 67.7 | (29.1-133.4) |
| Female | 7 | 14.4 | 48.7 | (19.5-100.3) | Female | 9 | 9.2 | 98.3 | (44.9-186.6) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 2.1 | nc | (nc-nc) | Male | 39 | 43.3 | 90.0 | (64.0-123.0) |
| Female | 296 | 312.6 | 94.7 | (84.2-106.1) | Female | 36 | 41.2 | 87.4 | (61.2-121.1) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 9 | 16.1 | 55.9 | (25.5-106.0) | Male | 29 | 29.6 | 98.1 | (65.7-140.9) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 102 | 111.0 | 91.9 | (74.9-111.6) | Female | 36 | 34.1 | 105.6 | (74.0-146.2) |
| Female | 90 | 115.2 | 78.1 | (62.8-96.0) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 18 | 21.9 | 82.2 | (48.7-130.0) |
| Male | 10 | 19.2 | 52.0 | (24.9-95.6) | Female | 23 | 24.8 | 92.6 | (58.7-138.9) |
| Female | 7 | 5.8 | 120.1 | (48.1-247.5) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 274 | 285.0 | 96.1 | (85.1-108.2) |
| Male | 11 | 10.7 | 102.8 | (51.3-184.0) | <u>Stomach</u> | | | | |
| Female | 3 | 8.8 | nc | (nc-nc) | Male | 20 | 18.5 | 108.0 | (65.9-166.8) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 19 | 12.2 | 155.6 | (93.7-243.0) |
| Male | 22 | 34.9 | 63.0 | (39.5-95.4) | <u>Testis</u> | | | | |
| Female | 20 | 23.6 | 84.8 | (51.7-130.9) | Male | 18 | 21.1 | 85.4 | (50.6-135.0) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 10 | 12.0 | 83.4 | (39.9-153.4) | Male | 18 | 13.6 | 132.5 | (78.5-209.4) |
| Female | 3 | 3.6 | nc | (nc-nc) | Female | 45 | 47.1 | 95.5 | (69.6-127.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 17 | 26.9 | 63.2 | (36.8-101.2) | Female | 75 | 66.5 | 112.8 | (88.8-141.5) |
| Female | 19 | 22.0 | 86.2 | (51.9-134.6) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 894 | 1034.7 | 86.4 | (80.8-92.3) |
| Male | 21 | 16.7 | 125.9 | (77.9-192.5) | Female | 971 | 1083.1 | 89.6 | (84.1-95.5) |
| Female | 12 | 6.3 | 191.0 | (98.6-333.7) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 106 | 139.3 | 76.1 | (62.3-92.0) | | | | | |
| Female | 106 | 143.4 | 73.9 | (60.5-89.4) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

| | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> | | <u>Obs</u> | <u>Exp</u> | <u>SIR</u> | <u>95% CI</u> |
|-------------------------------------------------|------------|------------|------------|---------------|--------------------------------------------|------------|------------|------------|---------------|
| <u>Bladder, Urinary</u> | | | | | <u>Melanoma of Skin</u> | | | | |
| Male | 24 | 26.4 | 91.1 | (58.3-135.5) | Male | 13 | 15.2 | 85.5 | (45.5-146.3) |
| Female | 17 | 10.7 | 159.5 | (92.9-255.4) | Female | 8 | 12.8 | 62.3 | (26.8-122.7) |
| <u>Brain and Other Nervous System</u> | | | | | <u>Multiple Myeloma</u> | | | | |
| Male | 4 | 4.7 | nc | (nc-nc) | Male | 4 | 4.1 | nc | (nc-nc) |
| Female | 2 | 4.1 | nc | (nc-nc) | Female | 4 | 3.2 | nc | (nc-nc) |
| <u>Breast</u> | | | | | <u>Non-Hodgkin Lymphoma</u> | | | | |
| Male | 1 | 0.8 | nc | (nc-nc) | Male | 10 | 13.5 | 73.8 | (35.3-135.8) |
| Female | 86 | 96.6 | 89.0 | (71.2-109.9) | Female | 14 | 13.4 | 104.2 | (56.9-174.8) |
| <u>Cervix Uteri</u> | | | | | <u>Oral Cavity and Pharynx</u> | | | | |
| Female | 3 | 4.0 | nc | (nc-nc) | Male | 5 | 9.5 | 52.6 | (17.0-122.8) |
| <u>Colon / Rectum</u> | | | | | <u>Ovary</u> | | | | |
| Male | 42 | 38.5 | 109.1 | (78.6-147.5) | Female | 3 | 10.5 | nc | (nc-nc) |
| Female | 49 | 41.6 | 117.9 | (87.2-155.9) | <u>Pancreas</u> | | | | |
| <u>Esophagus</u> | | | | | Male | 10 | 7.7 | 129.7 | (62.1-238.6) |
| Male | 8 | 6.6 | 121.1 | (52.1-238.6) | Female | 9 | 9.0 | 99.8 | (45.5-189.4) |
| Female | 1 | 2.1 | nc | (nc-nc) | <u>Prostate</u> | | | | |
| <u>Hodgkin Lymphoma</u> | | | | | Male | 102 | 98.4 | 103.6 | (84.5-125.8) |
| Male | 3 | 1.9 | nc | (nc-nc) | <u>Stomach</u> | | | | |
| Female | 2 | 1.5 | nc | (nc-nc) | Male | 7 | 6.4 | 108.5 | (43.5-223.6) |
| <u>Kidney and Renal Pelvis</u> | | | | | Female | 3 | 4.5 | nc | (nc-nc) |
| Male | 14 | 11.5 | 122.1 | (66.7-204.9) | <u>Testis</u> | | | | |
| Female | 7 | 7.7 | 91.0 | (36.5-187.6) | Male | 2 | 3.0 | nc | (nc-nc) |
| <u>Larynx</u> | | | | | <u>Thyroid</u> | | | | |
| Male | 2 | 4.1 | nc | (nc-nc) | Male | 4 | 3.3 | nc | (nc-nc) |
| Female | 1 | 1.2 | nc | (nc-nc) | Female | 17 | 10.6 | 161.0 | (93.7-257.7) |
| <u>Leukemia</u> | | | | | <u>Uteri Corpus and Uterus, NOS</u> | | | | |
| Male | 7 | 8.3 | 83.9 | (33.6-172.9) | Female | 19 | 20.5 | 92.8 | (55.8-144.9) |
| Female | 8 | 7.2 | 110.9 | (47.7-218.4) | <u>All Sites / Types</u> | | | | |
| <u>Liver and Intrahepatic Bile Ducts</u> | | | | | Male | 331 | 343.8 | 96.3 | (86.2-107.2) |
| Male | 5 | 5.5 | 90.8 | (29.3-211.8) | Female | 336 | 345.3 | 97.3 | (87.2-108.3) |
| Female | 4 | 2.2 | nc | (nc-nc) | | | | | |
| <u>Lung and Bronchus</u> | | | | | | | | | |
| Male | 41 | 48.9 | 83.9 | (60.2-113.8) | | | | | |
| Female | 46 | 48.8 | 94.2 | (69.0-125.6) | | | | | |

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;